var title_f31_29_32208="Achilles tendon xanthoma";
var content_f31_29_32208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achilles tendon xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A xanthoma of the Achilles tendon in a patient with heterozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32208=[""].join("\n");
var outline_f31_29_32208=null;
var title_f31_29_32209="Doppler pulmonic stenosis";
var content_f31_29_32209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler of pulmonary stenosis before and after balloon valvulopasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Doppler signal is directed through the suprasternal notch. Prior to valvuloplasty (panel 1) the estimated peak systolic gradient is 35 to 40 mmHg; however, the Doppler underestimates the peak gradient because sampling of flow may not be axial. After valvuloplasty (panel 2) there is a decrease in peak velocity to 2 m/sec and the estimated gradient is 16 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32209=[""].join("\n");
var outline_f31_29_32209=null;
var title_f31_29_32210="Subclavian steal physiology";
var content_f31_29_32210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Subclavian steal physiology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subclavian artery occlusion or a hemodynamically significant stenosis proximal to the origin of the vertebral artery results in lower pressure in the distal subclavian artery. As a result, blood is \"stolen\" from the cerebral circulation to perfuse the arm. Blood flows up the contralateral vertebral artery to the basilar artery, and retrograde down the ipsilateral vertebral artery away from the brainstem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32210=[""].join("\n");
var outline_f31_29_32210=null;
var title_f31_29_32211="Sulfanilamide: Patient drug information";
var content_f31_29_32211=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulfanilamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/17/39186?source=see_link\">",
"     see \"Sulfanilamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10360990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AVC&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10526085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10526084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulfanilamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10526089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10526090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10526092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have many vaginal infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10526087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696219",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10526088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10526093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10526094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15618 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-8FC26C7E2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32211=[""].join("\n");
var outline_f31_29_32211=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10360990\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526085\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526084\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526089\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526090\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526092\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526087\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526088\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526093\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10526094\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/17/39186?source=related_link\">",
"      Sulfanilamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_29_32212="Tesamorelin: Drug information";
var content_f31_29_32212=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tesamorelin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/1/43028?source=see_link\">",
"    see \"Tesamorelin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11390169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Egrifta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F11221401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Growth Hormone Releasing Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F11257075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV-associated lipodystrophy:",
"     </b>",
"     SubQ: 2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F11257073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14296792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14296793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F11257076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue if symptoms of hypersensitivity occur. Consider discontinuing with persistent elevations of IGF-1 (eg, &gt;3 standard deviation scores).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11390170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Egrifta&reg;: 1 mg, 2 mg [contains mannitol; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11384645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In order to prescribe Egrifta&trade;, healthcare providers must call the Axis Center at 1-877-714-2947. Egrifta&trade; is only available through specialty pharmacy distribution.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11257077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: The abdomen is the preferred site of administration; rotate site within the abdomen. Avoid injection into scar tissue, bruises, or the navel. The reconstituted solution should be visually inspected for particulate matter and discoloration; do not administer if solution is not clear, colorless and free of particulate matter.",
"     <b>",
"      Note:",
"     </b>",
"     Syringes and needles are single-use only and should not be shared between patients.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F11219350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11256605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tesamorelin may be confused with temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F11256769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The incidence of adverse reactions generally decreases with treatment continued beyond 26 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (6% to 25%; includes erythema [1% to 9%], pruritus [2% to 8%], pain [4%], irritation [3%], hemorrhage [2%], swelling [2%], urticaria [2%], rash [1%])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal:  Arthralgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (2% to 6%), hypertension (1% to 2%), chest pain (1%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Hypoesthesia (2% to 4%), depression (2%), pain (2%), insomnia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (4%), pruritus (1% to 2%), urticaria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     increased (5%), hot flush (1%), hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (4%), vomiting (2% to 3%), dyspepsia (2%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Pain in extremity (3% to 6%), myalgia (1% to 6%), paresthesia (2% to 5%), carpal tunnel syndrome (2%), creatine phosphokinase increased (2%), muscle stiffness (2%), musculoskeletal pain (2%), joint stiffness (2%), peripheral neuropathy (2%), joint swelling (1%), muscle spasm (1%), muscle strain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions (1% to 4%), night sweats (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anemia, abdominal abscess, basal cell carcinoma, bipolar II disorder, cellulitis, cerebellar syndrome,  chorioretinopathy, coronary artery arteriosclerosis, dehydration,  diarrhea, fracture, heart failure (congestive), mental status changes, pneumonia,  rectal cancer, sepsis, small intestinal obstruction, spontaneous abortion, trigeminal neuralgia, upper respiratory tract infection, viral bronchitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11256615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tesamorelin, mannitol, or any component of the formulation; disruption of hypothalamic-pituitary-axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma; active malignancy (newly diagnosed or recurrent); pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11256616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions (eg, pruritus, erythema, flushing, urticaria, rash) may occur. If hypersensitivity is suspected; discontinue and instruct patient to seek immediate medical attention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluid retention: Use may result in peripheral edema manifested by increased skin turgor and musculoskeletal discomfort. May be transient or resolve upon treatment discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Injection site reactions: Injection site reactions (including erythema, pruritus, pain, irritation, and bruising) may occur; incidence decreases with treatment continued beyond 26 weeks. Rotating the site of injection to different areas of the abdomen may reduce incidence of reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes: May increase risk of development of diabetes due to glucose intolerance. Evaluate glucose status prior to treatment initiation; monitor periodically for glucose metabolism changes. Patients with diabetes should be monitored for the development or worsening of retinopathy due to increased IGF-1 levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy: Release of endogenous growth hormone and increased serum IGF-1 may increase the risk for development or reactivation of malignancies. Use is contraindicated in patients with active malignancies; treatment for prior malignancy should be completed prior to initiation of tesamorelin. IGF-1 levels should be monitored during treatment; consider discontinuing with persistent IGF-1 elevations (eg, &gt;3 standard deviation scores).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acute critical illness: Growth hormone is associated with an increased risk of mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, trauma, or acute respiratory failure. Consider discontinuing in critically ill patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Should not be used in children due to risk of excess growth (gigantism) when epiphyses are open.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Not indicated for weight loss management. Due to a lack of long-term cardiovascular safety/benefit data, carefully consider whether continuation of treatment is warranted in patients who do not demonstrate efficacy (based on degree of reduction of visceral adipose tissue). There is no data supporting improved compliance of antiretroviral therapy with concomitant tesamorelin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11429708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cortisone: Tesamorelin may decrease serum concentrations of the active metabolite(s) of Cortisone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Tesamorelin may decrease serum concentrations of the active metabolite(s) of PredniSONE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11256611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11256612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies. During pregnancy, there is an increased deposition of visceral adipose tissue due to metabolic and hormonal changes.  Tesamorelin decreases the deposition of visceral fat and could potentially cause harm to the unborn fetus. Therefore, use during pregnancy is contraindicated; if pregnancy occurs during treatment, discontinue tesamorelin.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F11256613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11256614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In the United States where formula is accessible, affordable, safe, and sustainable, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Egrifta Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (1): $47.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (1): $94.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11257080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum IGF-1 levels should be monitored at baseline and during therapy due to the potential increased risk of malignancy from sustained elevation of IGF-1 levels. Serum glucose (prior to treatment initiation); monitor periodically for glucose metabolism changes. Monitor for retinopathy in patients with diabetes. Visceral adipose tissue (by waist circumference or CT scan). Monitor for fluid retention.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F11257065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tesamorelin binds to pituitary growth hormone-releasing factor (GRF) receptors and stimulates the secretion of endogenous growth hormone which has anabolic and lipolytic properties.  Growth hormone exerts its effects by interacting with receptors on target cells such as osteoblasts, myocytes, hepatocytes, and adipocytes to promote the reduction of total fat mass.  These effects are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F11257067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution:  V",
"     <sub>",
"      d",
"     </sub>",
"     :  Healthy adults: 9.4 &plusmn; 3.1 L/kg; HIV-infected patients: 10.5 &plusmn; 6.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: Healthy adults: &lt;4%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Healthy adults: 26 minutes; HIV-infected patients: 38 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 9 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Falutz J, Mamputu JC, Potvin D, et al, &ldquo;Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients With Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo Controlled Phase 3 Trials With Safety Extension Data,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(9):4291-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32212/abstract-text/20554713/pubmed\" id=\"20554713\" target=\"_blank\">",
"        20554713",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sivakumar T, Mechanic O, Fehmie DA, et al, &ldquo;Growth Hormone Axis Treatments for HIV-Associated Lipodystrophy: A Systematic Review of Placebo-Controlled Trials,&rdquo;",
"      <i>",
"       HIV Med",
"      </i>",
"      , 2011, 12(8):453-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32212/abstract-text/21265979/pubmed\" id=\"21265979\" target=\"_blank\">",
"        21265979",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stanley TL, Chen CY, Branch KL, et al, &ldquo;Effects of a Growth Hormone-Releasing Hormone Analog on Endogenous GH Pulsatility and Insulin Sensitivity in Healthy Men,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2011, 96(1):150-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32212/abstract-text/20943777/pubmed\" id=\"20943777\" target=\"_blank\">",
"        20943777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stanley TL, Falutz J, Mamputu JC, et al, &ldquo;Effects of Tesamorelin on Inflammatory Markers in HIV Patients With Excess Abdominal Fat: Relationship With Visceral Adipose Reduction,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2011, 25(10):1281-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32212/abstract-text/21516030/pubmed\" id=\"21516030\" target=\"_blank\">",
"        21516030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16092 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32212=[""].join("\n");
var outline_f31_29_32212=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390169\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11221401\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257075\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257073\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14296792\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14296793\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257076\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390170\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11384645\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257077\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11219350\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256605\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256769\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256615\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256616\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300118\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11429708\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256611\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256612\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256613\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11256614\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322877\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257080\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257065\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11257067\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16092|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/1/43028?source=related_link\">",
"      Tesamorelin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_29_32213="Chemo emetic pathways";
var content_f31_29_32213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Pathways by which chemotherapeutic agents may produce an emetic response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chemotherapy-induced emesis&nbsp;results from stimulation of a multistep reflex pathway that is controlled by the brain and triggered by afferent impulses to the vomiting center&nbsp;from the chemoreceptor trigger zone, gastrointestinal tract (by way of vagal afferent fibers), and possibly, the cerebral cortex. The mechanism that is best supported by research involves an effect of chemotherapy&nbsp;on the upper small intestine.&nbsp;Local generation of&nbsp;free radicals&nbsp;leads to localized exocytotic release of 5-hydroxytryptamine (5-HT) from the enterochromaffin cells; 5-HT then interacts with 5-hydroxytryptamine3 (5-HT",
"    <sub>",
"     3",
"    </sub>",
"    ) receptors on vagal afferent terminals in the wall of the bowel. This stimulates vagal afferent fibers, which project to the dorsal brain stem, primarily to the nucleus tractus solitarius (NTS), and, to a lesser extent, the area postrema (AP), the two parts of the brain referred to collectively as the dorsal vagal complex (and also referred to as the chemoreceptor trigger zone).&nbsp;Neural fibers project from the dorsal vagal complex to the final effector of the emetic reflex, the vomiting center, which is an anatomically indistinct area occupying a more ventral location in the medulla. Antineoplastic agents may also induce emesis through a direct&nbsp;interaction with the AP.&nbsp;Other potential sources of afferent input to the vomiting center&nbsp;that result in emesis after chemotherapy include a number of structures in the temporal lobe, such as the amygdala. Evidence for this pathway is less well established than for other proposed sites of chemotherapeutic action.",
"    <div class=\"footnotes\">",
"     CNS: central nervous system; AP: area postrema; NTS: nucleus tractus solitarius",
"    </div>",
"    <div class=\"reference\">",
"     Modified&nbsp;from Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358:2482.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32213=[""].join("\n");
var outline_f31_29_32213=null;
var title_f31_29_32214="Cervical pregnancy";
var content_f31_29_32214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 612px\">",
"   <div class=\"ttl\">",
"    Cervical pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 592px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three views of cervical ectopic pregnancy obtained at different field of views. (Panel A) A gestational sac is seen in the cervix (G). Closer inspection shows a yolk sac and tiny embryo (Panel B) with cardiac activity (Panel C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32214=[""].join("\n");
var outline_f31_29_32214=null;
var title_f31_29_32215="Tranylcypromine: Drug information";
var content_f31_29_32215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tranylcypromine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/42/39589?source=see_link\">",
"    see \"Tranylcypromine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Parnate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Parnate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Monoamine Oxidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Usual effective dose: 30 mg/day in divided doses; if symptoms don&rsquo;t improve after 2 weeks, increase by 10 mg increments at 1- to 3-week intervals; maximum: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Transitioning from another MAO inhibitor or dibenzazepine derivative (eg, TCAs, carbamazepine, cyclobenzaprine) to tranylcypromine therapy:",
"     </i>",
"     Allow at least 1 medication-free week, then initiate tranylcypromine at 50% of usual starting dose for at least 1 week.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parnate&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7875056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088674.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088674.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive episode without melancholia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F230013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, orthostatic hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, chills, dizziness, drowsiness, headache, insomnia, mania, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (rare), rash (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Sexual dysfunction (anorgasmia, ejaculatory disturbances, impotence); SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasm, myoclonus, numbness, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Akinesia, ataxia, confusion, cystic acne, disorientation, memory loss, mouth fissures, polyuria, scleroderma (localized), urinary incontinence, urticaria, withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular disease (including hypertension); cerebrovascular defect; history of headache; history of hepatic disease or abnormal liver function tests; pheochromocytoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Concurrent use of antihistamines, antihypertensives, antiparkinson drugs, bupropion, buspirone, caffeine (excessive use), CNS depressants (including ethanol and narcotics),  dextromethorphan, diuretics, elective surgery requiring general anesthesia (discontinue tranylcypromine &ge;10 days prior to elective surgery), local vasoconstrictors, meperidine, MAO inhibitors or dibenzazepine derivatives (eg, amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline, doxepin, carbamazepine, cyclobenzaprine, amoxapine, maprotiline, trimipramine), SSRIs or SNRIs, spinal anesthesia (hypotension may be exaggerated), sympathomimetics (including amphetamines, cocaine, phenylephrine, pseudoephedrine) or related compounds (methyldopa, reserpine, levodopa, tryptophan), or foods high in tyramine content",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Bupropion: At least 14 days should elapse between MAO inhibitor discontinuation and bupropion initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Buspirone: At least 10 days should elapse between tranylcypromine discontinuation and buspirone initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     MAO inhibitors or dibenzazepine derivatives: At least 1-2 weeks should elapse between the use of another MAO inhibitor or dibenzazepine derivative and tranylcypromine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Meperidine: At least 2-3 weeks should elapse between MAO inhibitor discontinuation and meperidine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     SSRIs or SNRIs: At least 2 weeks should elapse between the discontinuation of sertraline or paroxetine and the initiation of tranylcypromine. At least 5 weeks should elapse between the discontinuation of fluoxetine and the initiation of tranylcypromine. At least 1 week should elapse between discontinuation of a SNRI and the initiation of tranylcypromine. At least 2 weeks should elapse between the discontinuation of tranylcypromine and the initiation of SNRIs and SSRIs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Tranylcypromine is not FDA approved for treatment of children and adolescents.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertensive crisis: Cases of hypertensive crisis (sometimes fatal) have occurred; symptoms include: severe headache, nausea/vomiting, neck stiffness/soreness, photophobia, and sweating. Monitor blood pressure closely in all patients. May occur with foods/supplements high in tyramine, tryptophan, phenylalanine, or tyrosine content; treatment with phentolamine is recommended for hypertensive crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (especially at dosages &gt;30 mg/day); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; sensitization to the effects of insulin may occur, monitor blood glucose closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists especially in patients using excessive doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Tranylcypromine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Do not use with other MAO inhibitors or antidepressants. Do not use within 5 weeks of fluoxetine discontinuation or 1 week of other antidepressant discontinuation. Avoid products containing sympathomimetic stimulants or dextromethorphan. Concurrent use with antihypertensive agents may lead to exaggeration of hypotensive effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Tranylcypromine is not generally considered a first-line agent for the treatment of depression; tranylcypromine is typically used in patients who have failed to respond to other treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelography: Discontinue at least 48 hours prior to myelography; do not resume therapy until at least 24 hours after procedure.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2A6 (strong), CYP2C19 (moderate), CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (moderate), CYP2E1 (weak), CYP3A4 (weak), Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F229987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Beverages containing tyramine (eg, hearty red wine and beer) may increase toxic effects. Management: Avoid ethanol and beverages containing tyramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Kava kava, valerian, St John's wort, and SAMe may increase risk of serotonin syndrome and/or excessive sedation. Supplements containing caffeine, tyrosine, tryptophan, or phenylalanine may increase the risk of severe side effects like hypertensive reactions or serotonin syndrome. Management: Avoid kava kava, valerian, St John's wort, SAMe, and supplements containing caffeine, tyrosine, tryptophan, or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13968052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F230000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F229981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid tyramine-containing foods/beverages. Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment where tyramine concentrations may increase.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F229980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Parnate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $673.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tranylcypromine Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $360.89",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F229968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose; blood pressure, mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F229982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Jatrosom (DE);",
"     </li>",
"     <li>",
"      Parnate (AE, AR, AU, BF, BH, BJ, BR, CI, CY, DE, EG, ES, ET, GB, GH, GM, GN, IE, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tranylcypromine is a nonhydrazine monoamine oxidase inhibitor. It increases endogenous concentrations of epinephrine, norepinephrine, dopamine, and serotonin through inhibition of the enzyme (monoamine oxidase) responsible for the breakdown of these neurotransmitters.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: 2 days to 3 weeks continued dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: MAO inhibition may persist for up to 10 days following discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 90-190 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blansjaar BA and Egberts TC, &ldquo;Delirium in a Patient Treated With Disulfiram and Tranylcypromine,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(2):296.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brady KT, Lydiard RB, and Kellner C, &ldquo;Tranylcypromine Abuse,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1991, 148(9):1268-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brubacher JF, Lurin MJ, Hirsch S, et al, &ldquo;Serotonin Syndrome From Venlafaxine-Tranylcypromine Interaction,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):523-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chatterjee A and Tosyali MC, &ldquo;Thrombocytopenia and Delirium Associated With Tranylcypromine Overdose,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1995, 15(2):143-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/7782490/pubmed\" id=\"7782490\" target=\"_blank\">",
"        7782490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Georgotas A, Friedman E, McCarthy M, et al, &ldquo;Resistant Geriatric Depression and Therapeutic Response to Monoamine-Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 1983, 18:195-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/6830930/pubmed\" id=\"6830930\" target=\"_blank\">",
"        6830930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goff DC and Jenike MA, &ldquo;Treatment-Resistant Depression in the Elderly,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1986, 34(1):63-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/3510242/pubmed\" id=\"3510242\" target=\"_blank\">",
"        3510242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodgman M, Martin T, Dean B, et al, &ldquo;Severe Serotonin Syndrome Secondary to Venlafaxine and Maintenance Tranylcypromine Therapy,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):554.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huyse FJ, Touw DJ, van Schijndel RS, et al, &ldquo;Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 2006, 47(1):8-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/16384803 /pubmed\" id=\"16384803 \" target=\"_blank\">",
"        16384803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenike MA, &ldquo;MAO Inhibitors as Treatment for Depressed Patients With Primary Degenerative Dementia (Alzheimer's Disease),&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      1985, 142:763.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lejoyeux M, et al, &ldquo;Serotonin Syndrome: Incidence, Symptoms, and Treatment,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 1994, 2:132-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sakkas P, Davis JM, Janicak PG, et al, &ldquo;Drug Treatment of the Neuroleptic Malignant Syndrome,&rdquo;",
"      <i>",
"       Psychopharmacol Bull",
"      </i>",
"      , 1991, 27(3):381-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/1685592/pubmed\" id=\"1685592\" target=\"_blank\">",
"        1685592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Psychiatr Ann",
"      </i>",
"      , 2001, 31(6):378-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;Refining the MAOI Diet: Tyramine Content of Pizzas and Soy Products,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1999, 60(3):191-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/10192596/pubmed\" id=\"10192596\" target=\"_blank\">",
"        10192596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Shulman KI, Tailor SA, et al, &ldquo;Tyramine Content of Previously Restricted Foods in Monoamine Oxidase Inhibitor Diets,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1996, 16(5):383-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/29/32215/abstract-text/8889911/pubmed\" id=\"8889911\" target=\"_blank\">",
"        8889911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10012 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32215=[""].join("\n");
var outline_f31_29_32215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708900\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229991\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229992\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230015\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229995\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229996\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229971\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229956\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7875056\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229974\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230013\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229977\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229960\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230009\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229965\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229987\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13968052\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230000\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229981\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229980\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229968\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229982\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229959\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229976\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10012\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10012|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/42/39589?source=related_link\">",
"      Tranylcypromine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_29_32216="Guttate psoriasis";
var content_f31_29_32216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Guttate psoriasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32216/contributors\">",
"     Stephanie Mehlis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32216/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32216/contributors\">",
"     Kristina Callis Duffin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32216/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/29/32216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1391875244\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is a common skin disorder characterized by the development of inflammatory plaques on the skin. The spectrum of clinical manifestations of psoriasis is wide, and includes chronic plaque, guttate, inverse, erythrodermic, pustular, and nail variants of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with guttate psoriasis typically present with the acute onset of numerous small, inflammatory, scaly plaques on the trunk and extremities (",
"    <a class=\"graphic graphic_picture graphicRef55141 graphicRef64836 \" href=\"mobipreview.htm?34/34/35368\">",
"     picture 1A-B",
"    </a>",
"    ). Guttate psoriasis is most common among children and young adults, and a preceding history of streptococcal infection is often present.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and treatment of guttate psoriasis will be reviewed here. Other manifestations of psoriasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391875258\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis occurs in 0.6 to 4.8 percent of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/1\">",
"     1",
"    </a>",
"    ], with chronic plaque psoriasis as the most common clinical presentation. Estimates of the proportion of patients with psoriasis who develop guttate disease vary widely; many studies cite a prevalence of less than 30 percent among patients with psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Guttate psoriasis is most frequently diagnosed in children and young adults under the age of 30; however, older individuals may also be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. As an example, in a Spanish study that compared 1092 patients in whom psoriasis began between the ages of 0 and 30 years to 662 patients with disease onset later in life, patients in the younger-onset group were significantly more likely to have the guttate variant (15 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sex predilection for guttate psoriasis has not been established. Both males and females may develop this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500968\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic and environmental factors likely contribute to the development of guttate psoriasis. The class I human leukocyte antigen HLA-Cw6 (in particular, the HLA Cw*0602 allele) and beta-hemolytic streptococci are the primary factors linked to the development of this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500143\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HLA-Cw*0602 allele is strongly associated with psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/10\">",
"     10",
"    </a>",
"    ]. In a meta-analysis of 18 studies with approximately 3400 patients with psoriasis and 3300 healthy controls, participants who were positive for HLA-Cw*0602 were more than four times more likely to have psoriasis than participants who were negative for the allele (OR 4.55, 95% CI 3.65-5.67) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/11\">",
"     11",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The association between psoriasis and the HLA-Cw*0602 allele appears to be particularly strong among patients with guttate psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/5,12-16\">",
"     5,12-16",
"    </a>",
"    ]. Examples of studies in support of an association include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an Icelandic study that evaluated the correlation between HLA-Cw6 status and disease characteristics in patients with familial psoriasis, 31 of 33 patients (94 percent) whose symptoms began as an acute guttate eruption demonstrated HLA-Cw6 positivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/16\">",
"       16",
"      </a>",
"      ]. An extension of this study that included patients without a family history of psoriasis (n = 1019) found the prevalence of guttate disease was significantly greater among HLA-Cw*0602 positive patients than among HLA-Cw*0602 negative patients (11 versus 3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Swedish case-control study, 56 of 77 patients with guttate psoriasis (73 percent) were positive for the HLA-Cw*0602 allele compared with 39 or 371 controls (11 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a United Kingdom study of 29 patients with guttate psoriasis and 604 controls, the HLA-Cw*0602 allele was detected in all patients with guttate psoriasis compared with only 20 percent of controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Chinese study found that HLA-Cw*0602 was strongly associated with guttate psoriasis; the guttate presentation accounted for 21 percent of psoriasis cases in HLA-Cw*0602 positive patients with psoriasis and 9 percent of psoriasis cases in HLA-Cw*0602 negative patients with psoriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500010\">",
"    <span class=\"h2\">",
"     Streptococcal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal infection often precedes the onset of guttate psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7,17-20\">",
"     7,17-20",
"    </a>",
"    ]. A link between these entities is supported by studies that have documented a relationship between new-onset guttate psoriasis and acute streptococcal pharyngitis in 56 to 97 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, perianal streptococcal infection has preceded guttate psoriasis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The cutaneous manifestations of guttate psoriasis typically develop two to three weeks after an associated streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New-onset guttate psoriasis may be more likely to be associated with streptococcal infections than guttate psoriasis that develops in patients with preexisting chronic plaque psoriasis. In a prospective study, 19 of 33 patients (58 percent) with acute guttate psoriasis versus 7 of 27 patients (26 percent) with guttate exacerbations of chronic psoriasis had serologic evidence for recent streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500017\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports have documented the development of guttate psoriasis following varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] and",
"    <em>",
"     Pityrosporum",
"    </em>",
"    folliculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A Koebner phenomenon, in which wound healing triggers hyperproliferative changes in the skin, may be a factor in these cases. Guttate psoriasis has also developed in the site of a tattoo, a finding consistent with the theory of Koebnerization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500846\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guttate psoriasis has been reported after treatment with tumor necrosis factor (TNF)-alpha inhibitors in case reports and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. The reason for this paradoxical observation is unclear, but may involve disruption of the cytokine milieu, leading to unopposed interferon production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391875265\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of guttate psoriasis in not well-understood. Interplay between genetic and environmental factors leading to an aberrant immune response in the skin may contribute to disease development.",
"   </p>",
"   <p>",
"    As noted above, strong associations between guttate psoriasis, streptococcal infection, and HLA-Cw*0602 positivity have been detected in patients with guttate psoriasis (see",
"    <a class=\"local\" href=\"#H2500968\">",
"     'Risk factors'",
"    </a>",
"    above). Examples of proposed mechanisms for the relationship between guttate psoriasis and streptococcal infection include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cross-reactivity between streptococcal M-proteins (the major pathogenic antigens on beta-hemolytic streptococci) presented to immune cells in the tonsils and structurally similar type I keratins in the epidermis (K16 and K17) trigger a T-cell mediated autoimmune response",
"     </li>",
"     <li>",
"      Streptococcal superantigens in the tonsils may augment the expression of the skin homing cutaneous lymphocyte antigen (CLA) on effector T cells, contributing to the migration of T cells into the skin; CD4+ cells migrate into the dermis and CD8+ cells migrate into the epidermis",
"     </li>",
"     <li>",
"      An innate immune-mediated inflammatory response occurs as a consequence of the binding of peptidoglycan or other streptococcal antigens to cell receptors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observed association between guttate psoriasis and HLA-Cw*0602 may be related to interactions between streptococci and this molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/12\">",
"     12",
"    </a>",
"    ]. In an in vitro study, homologous peptides from K17 and streptococcal M-protein that were predicted to bind to HLA-Cw6 were better able to stimulate IFN-gamma production in T cells (mostly CD8+ T cells that also demonstrated CLA) from patients with psoriasis than T cells obtained from patients without psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/34\">",
"     34",
"    </a>",
"    ]. Moreover, the greatest responses were detected in T cells derived from HLA-Cw*0602 positive patients with psoriasis.",
"   </p>",
"   <p>",
"    Clinical evidence of a relationship between HLA-Cw*0602 status, guttate psoriasis, and streptococcal infection was detected in a study of 439 patients with plaque psoriasis, 143 patients with guttate psoriasis, and 454 healthy controls. Patients with guttate psoriasis who were positive for HLA-Cw*0602 were more likely to have a positive streptococcal throat swab than patients who were HLA-Cw*0602 negative (odds ratio 3.5, 95% CI 1.5-8.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/13\">",
"     13",
"    </a>",
"    ]. A difference in throat swab positivity rates based upon HLA-Cw*0602 status was not detected among the healthy controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2499966\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guttate psoriasis is characterized by the acute eruption of numerous small, erythematous papules and plaques. The term &ldquo;guttate&rdquo; is utilized to refer to the discrete, drop-like appearance of skin lesions. The eruption may present as a new onset disorder in patients without a history of psoriasis or as a new presentation of psoriasis in patients with preexisting chronic plaque-type disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual lesions usually measure between 2 and 15 mm in diameter and demonstrate fine overlying scale (",
"    <a class=\"graphic graphic_picture graphicRef55141 graphicRef64836 \" href=\"mobipreview.htm?34/34/35368\">",
"     picture 1A-B",
"    </a>",
"    ). The trunk and proximal extremities are classically involved, although lesions may also occur in other sites, such as the scalp, hands, feet, and nails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7\">",
"     7",
"    </a>",
"    ]. Pruritus and postinflammatory hyperpigmentation may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391875279\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical examination is usually sufficient for the diagnosis of guttate psoriasis. A skin biopsy can be used to support the diagnosis in difficult cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500097\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic findings of guttate psoriasis vary with the age of the lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/35\">",
"     35",
"    </a>",
"    ]. The findings in early lesions may be nondiagnostic, demonstrating mild acanthosis, papillary dermal edema, capillary dilatation, and a sparse lymphocyte-predominant dermal infiltrate.",
"   </p>",
"   <p>",
"    Mature lesions more closely resemble the pathology findings in chronic plaque psoriasis. Such lesions have parakeratosis alternating with hyperkeratosis, epidermal acanthosis, rete ridge elongation, and collections of neutrophils in the epidermis that are also known as Munro microabscesses. Dermal findings include dilated, tortuous vessels and a superficial perivascular infiltrate containing lymphocytes, neutrophils, and macrophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500854\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;No serologic tests provide a definitive diagnosis of guttate psoriasis. Routine assessment for evidence of a streptococcal infection in patients without infectious symptoms is controversial because a benefit of antibacterial therapy in guttate psoriasis is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/36\">",
"     36",
"    </a>",
"    ]. In our opinion, laboratory testing is not necessary in patients without active signs or symptoms of streptococcal infection.",
"   </p>",
"   <p>",
"    Patients who present with symptoms suggestive of streptococcal pharyngitis or other forms of streptococcal infection should be evaluated with appropriate laboratory studies to facilitate the identification and treatment of these conditions. Symptoms of streptococcal pharyngitis include sore throat, tonsillar exudate, tender cervical adenitis, and fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Identifying GAS pharyngitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of acute pharyngitis in adults\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500104\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple disorders may present with clinical features that resemble guttate psoriasis. In most cases, the clinical history and physical examination are sufficient for differentiating guttate psoriasis from other diseases. Occasionally, laboratory studies are needed to assist with diagnosis.",
"   </p>",
"   <p>",
"    Examples of disorders in the differential diagnosis of guttate psoriasis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pityriasis rosea",
"      </strong>",
"      &ndash; Pityriasis rosea presents with the acute eruption of multiple, oval inflammatory plaques (",
"      <a class=\"graphic graphic_picture graphicRef53701 graphicRef57568 graphicRef87126 \" href=\"mobipreview.htm?26/51/27450\">",
"       picture 2A-C",
"      </a>",
"      ). Like guttate psoriasis, the trunk and proximal extremities are prominent sites of involvement. The classic features of a &ldquo;Christmas tree&rdquo; pattern distribution and collarette of scale can be useful clues for the identification of pityriasis rosea. At least 50 percent also develop a large oval plaque (also known as a herald plaque) prior to the development of the widespread eruption. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/18999?source=see_link\">",
"       \"Pityriasis rosea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tinea corporis",
"      </strong>",
"      &ndash; Extensive tinea corporis may present with numerous annular plaques on the skin (",
"      <a class=\"graphic graphic_picture graphicRef55949 graphicRef66102 \" href=\"mobipreview.htm?19/62/20456\">",
"       picture 3A-B",
"      </a>",
"      ). Peripheral scale and central clearing are commonly seen. A potassium hydroxide (KOH) preparation is useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary syphilis",
"      </strong>",
"      &ndash; Secondary syphilis is characterized by the development of erythematous to brown macules, papules, or small plaques in a generalized distribution (",
"      <a class=\"graphic graphic_picture graphicRef60313 graphicRef65500 \" href=\"mobipreview.htm?21/8/21639\">",
"       picture 4A-B",
"      </a>",
"      ). Involvement of the palms and soles suggests the possibility of this diagnosis. Serologic findings and histopathologic examination are also useful for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=see_link&amp;anchor=H13#H13\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Secondary syphilis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis lichenoides chronica",
"      </strong>",
"      &ndash; Pityriasis lichenoides chronica is an uncommon skin disorder that presents with recurrent crops of erythematous to brown papules on the trunk and proximal extremities (",
"      <a class=\"graphic graphic_picture graphicRef71210 \" href=\"mobipreview.htm?18/50/19233\">",
"       picture 5",
"      </a>",
"      ). Lesions often demonstrate an adherent (micaceous) scale. Pruritus may or may not be present. The disorder is most common in children and young adults.",
"     </li>",
"     <li>",
"      <strong>",
"       Small plaque parapsoriasis",
"      </strong>",
"      &ndash; Small plaque parapsoriasis is a rare condition in which multiple, small oval patches with fine scale develop on the trunk and proximal extremities. The eruption may be asymptomatic or mildly pruritic.",
"     </li>",
"     <li>",
"      <strong>",
"       Nummular dermatitis",
"      </strong>",
"      &ndash; Nummular dermatitis (also known as nummular eczema) may present with single or multiple oval, inflammatory plaques (",
"      <a class=\"graphic graphic_picture graphicRef58067 graphicRef66792 \" href=\"mobipreview.htm?33/55/34679\">",
"       picture 6A-B",
"      </a>",
"      ). Pruritus is typically prominent. Serous drainage may be present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of dermatitis\", section on 'Nummular dermatitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the cutaneous features of viral exanthems and maculopapular drug eruptions tend to differ from guttate psoriasis, the clinical scenarios in which guttate psoriasis develops (a new widespread skin eruption in a patient with a recent history of upper respiratory symptoms or a history of streptococcal pharyngitis treated with antibiotics) may lead to consideration of these diagnoses (",
"    <a class=\"graphic graphic_picture graphicRef83682 graphicRef54205 \" href=\"mobipreview.htm?37/38/38504\">",
"     picture 7A-B",
"    </a>",
"    ). Recognition of the well-defined plaques with adherent scale that are characteristic of guttate psoriasis is useful for distinguishing this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2501744\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guttate psoriasis may spontaneously remit, typically over the course of several weeks to several months, may intermittently recur, or may persist and progress into chronic plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7,37,38\">",
"     7,37,38",
"    </a>",
"    ]. Few data are available on the prognosis of guttate psoriasis, precluding reliable predictions about the disease course in individual patients.",
"   </p>",
"   <p>",
"    Disease remission was the most common course followed in a retrospective study of 36 patients with childhood or adult-onset guttate psoriasis who lacked a preceding history of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7\">",
"     7",
"    </a>",
"    ]. Complete remission lasting for at least one year occurred in 22 patients (61 percent) with a mean time to disease clearance of 3.9 &plusmn; 2.4 months, and the remaining 14 patients progressed to chronic plaque-type disease. Of note, three patients in the remission group had recurrence after one year. A wide variety of treatments for guttate psoriasis were utilized in the patients in this study.",
"   </p>",
"   <p>",
"    A separate series that included 44 patients with guttate psoriasis followed for a least one year found a higher rate of transformation into chronic plaque psoriasis; 28 patients (68 percent) developed chronic plaque-type disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1391875286\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatments used for guttate psoriasis overlap with those utilized for chronic plaque psoriasis. Although many treatments for chronic plaque psoriasis have been extensively studied, investigations focused specifically on treatment results in guttate psoriasis are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link\">",
"     \"Treatment of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the possibility for spontaneous remission of guttate psoriasis within several weeks or several months, foregoing treatment is an option for patients who prefer to avoid therapy. However, since the time required for disease remittance is unpredictable and persistence of psoriasis is not uncommon, in our experience, many patients elect to proceed with treatment. (See",
"    <a class=\"local\" href=\"#H2501744\">",
"     'Clinical course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    First-line treatments for guttate psoriasis include phototherapy and topical agents. Although systemic antibiotic therapy has been advocated by some authors, the value of such treatment is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, data on the efficacy of tonsillectomy, which aims to permanently remove a focus of streptococcal infection, are limited. Patients who progress to chronic plaque psoriasis can be managed according to the treatment approach for this variant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of psoriasis\", section on 'Approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500863\">",
"    <span class=\"h2\">",
"     First-line therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500111\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet (UV) phototherapy is considered a first-line therapy for guttate psoriasis. This designation is primarily due to its documented efficacy in other forms of psoriasis, its relative safety, and the ability to easily treat large body surface areas. The options for full-body phototherapy for psoriasis include narrowband UVB, broadband UVB, and psoralen plus UVA (PUVA) phototherapy.",
"   </p>",
"   <p>",
"    The efficacy of phototherapy for plaque psoriasis is well documented, with narrowband UVB considered the preferred form of phototherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Narrowband UVB has been more effective than broadband UVB in multiple small, prospective split-body studies of patients with plaque-type psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]. Although a randomized trial that compared narrowband UVB to a selective broadband UVB device in 100 patients with plaque-type psoriasis found a difference of efficacy in favor of narrowband UVB that was not statistically significant (56 versus 40 percent of patients achieved disease clearance), the study was underpowered to detect a difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/44\">",
"     44",
"    </a>",
"    ]. PUVA was significantly more effective than narrowband UVB in a randomized trial (n = 93). However, the requirement for strict photoprotection following treatment makes PUVA a less favorable choice for therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=see_link\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Formal study of the efficacy of phototherapy in guttate psoriasis is limited since most psoriasis studies that have included patients with this variant have failed to stratify treatment results according to the type of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/39\">",
"     39",
"    </a>",
"    ]. An open study of 53 patients with various forms of psoriasis found that all patients with guttate psoriasis (n = 12) improved with narrowband UVB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse effects of phototherapy include burns, pruritus, and premature skin aging. Increased risks for squamous cell carcinoma and possibly melanoma are associated with long-term PUVA therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=see_link&amp;anchor=H31513976#H31513976\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Skin cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients without access to phototherapy may experience improvement in guttate psoriasis with cautious outdoor sun exposure. The efficacy of this intervention has not been formally evaluated. Based upon clinical experience, five to ten minutes of noontime sun exposure without sunscreen is typically sufficient. Sunburns should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500118\">",
"    <span class=\"h3\">",
"     Topical corticosteroids and vitamin D analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials have supported the efficacy of topical corticosteroids and topical vitamin D analogs for chronic plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/47\">",
"     47",
"    </a>",
"    ]. These agents have not been formally evaluated specifically in guttate disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential impediment to topical treatment of guttate psoriasis is the often widespread nature of the disease, which can make the application of topical agents impractical. Thus, phototherapy is usually preferred for the treatment of patients with numerous lesions. Topical agents may be used as an adjunct to phototherapy. (See",
"    <a class=\"local\" href=\"#H2500111\">",
"     'Phototherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cutaneous atrophy is a potential adverse effect of topical corticosteroid therapy. To minimize this risk, low potency agents are typically used on atrophy-prone sites such as the face and intertriginous areas (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). Medium to high potency agents may be applied to lesions on the trunk or extremities.",
"   </p>",
"   <p>",
"    Topical corticosteroids are typically applied to active lesions once to twice daily for around two weeks. Longer courses may be utilized if necessary; however, monitoring for adverse effects is essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of psoriasis\", section on 'Corticosteroids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical vitamin D analogs, such as calcitriol or calcipotriene, may be used alone or in conjunction with topical corticosteroid therapy. Cutaneous irritation is the most common adverse effect of these agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of psoriasis\", section on 'Topical vitamin D analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500909\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a minority of patients, guttate psoriasis recurs multiple times per year or fails to improve with phototherapy or topical therapies. Although few data are available to support their use, tonsillectomy and systemic therapies used for chronic plaque psoriasis have been utilized in the management of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2500132\">",
"    <span class=\"h3\">",
"     Tonsillectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution of recurrent",
"    <em>",
"     Streptococcus",
"    </em>",
"    -associated guttate and chronic plaque psoriasis following tonsillectomy has been documented in several case reports and uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. However, no randomized trials have evaluated the efficacy of this intervention. In one uncontrolled study, five out of six patients with guttate psoriasis that flared with episodes of tonsillitis had complete clearance of the disease after tonsillectomy, and the remaining patient had a lesser degree of improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/51\">",
"     51",
"    </a>",
"    ]. In contrast, only two of seven patients with chronic plaque psoriasis cleared.",
"   </p>",
"   <p>",
"    Based upon this data, it is conceivable that tonsillectomy may be effective for some patients with recurrent, tonsillitis-associated guttate psoriasis. However, data are insufficient to recommend the routine use of tonsillectomy, and further studies are necessary to evaluate the efficacy of this treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6761?source=see_link\">",
"     \"Tonsillectomy in adults: Surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=see_link\">",
"     \"Tonsillectomy and adenoidectomy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2502831\">",
"    <span class=\"h3\">",
"     Systemic psoriasis therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon efficacy demonstrated in chronic plaque psoriasis, treatment with systemic immunomodulatory and immunosuppressive therapies utilized for chronic plaque psoriasis may be attempted in patients with persistent disease that fails to respond to first-line therapies. However, there is a lack of published evidence on the efficacy of these treatments specifically in guttate psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of psoriasis\", section on 'Systemic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H716080\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2501654\">",
"    <span class=\"h3\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the well-accepted association between streptococcal infection and guttate psoriasis, antibiotic therapy has been proposed as a treatment for this disease (see",
"    <a class=\"local\" href=\"#H2500010\">",
"     'Streptococcal infection'",
"    </a>",
"    above). However, data on the efficacy of antibiotic therapy are limited and conflicting. Evidence in support of antistreptococcal antibiotics is limited to a few uncontrolled studies that document improvement in guttate or plaque-type psoriasis after treatment with macrolides or treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    given with or without other antistreptococcal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. In a randomized trial in 20 patients with psoriasis (19 with guttate psoriasis) that compared 14 days of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (both 250 mg four times daily) plus rifampin (300 mg twice daily) during the final five days of therapy to a 14-day treatment regimen consisting of penicillin or erythromycin monotherapy, neither treatment approach reduced disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential role for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    therapy resurfaced in a subsequent prospective uncontrolled study of 52 patients with guttate psoriasis. Monotherapy with rifampin (600 mg per day) for 60 days was associated with reductions of psoriasis severity scores regardless of the presence or absence of evidence of recent streptococcal infection. Based upon this finding, the authors postulated that immunomodulatory effects of rifampin may have contributed to the observed effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, data remain insufficient to support a routine recommendation for antibiotic therapy for skin disease in guttate psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32216/abstract/49\">",
"     49",
"    </a>",
"    ]. However, patients with active sources of streptococcal infection (eg, streptococcal pharyngitis or perianal streptococcal infection) should be treated with antibiotic therapy to resolve these infections as indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2503181\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guttate psoriasis is a variant of psoriasis that is characterized by the presence of small, erythematous papules and plaques on the skin. Guttate psoriasis is most frequently diagnosed in adolescents and young adults, but may occur in other age groups. (See",
"      <a class=\"local\" href=\"#H1391875258\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic and environmental factors likely contribute to the development of guttate psoriasis. The HLA-Cw*0602 allele has been strongly linked to this disorder and streptococcal infection often precedes its development. The latency period between streptococcal infection and the appearance of skin lesions is typically two to three weeks. (See",
"      <a class=\"local\" href=\"#H2500968\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relationship between streptococcal infection and guttate psoriasis is not fully understood. Cross-reactivity between streptococcal and epidermal antigens, stimulatory effects of streptococcal superantigens,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the induction of an innate immune response by streptococcal components may be involved. (See",
"      <a class=\"local\" href=\"#H1391875265\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The skin lesions of guttate psoriasis are typically 2 to 15 mm in diameter with overlying fine scale (",
"      <a class=\"graphic graphic_picture graphicRef55141 graphicRef64836 \" href=\"mobipreview.htm?34/34/35368\">",
"       picture 1A-B",
"      </a>",
"      ). The trunk and proximal extremities are the principle sites of involvement. (See",
"      <a class=\"local\" href=\"#H2499966\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of guttate psoriasis can usually be made by clinical examination. In difficult cases, a skin biopsy may be used to support the diagnosis and rule out other conditions. (See",
"      <a class=\"local\" href=\"#H1391875279\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guttate psoriasis may spontaneously remit over the course of several weeks to months, or may persist and progress to chronic plaque disease. The course of the disease is unpredictable. (See",
"      <a class=\"local\" href=\"#H2501744\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with widespread lesions of guttate psoriasis who desire treatment, we suggest treatment with narrowband UVB phototherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Topical corticosteroids, topical vitamin D analogs, and other forms of phototherapy are alternative treatments. (See",
"      <a class=\"local\" href=\"#H2500863\">",
"       'First-line therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with the systemic immunomodulatory and immunosuppressive agents utilized for plaque psoriasis may be attempted in patients with guttate psoriasis that fails to improve with phototherapy and topical therapies. The efficacy of such treatment in guttate psoriasis has not been well-studied. (See",
"      <a class=\"local\" href=\"#H2502831\">",
"       'Systemic psoriasis therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of tonsillectomy and systemic antibiotic therapy for the treatment of the skin manifestations of guttate psoriasis is controversial. Further study is necessary to explore the efficacy of these interventions. These interventions are not recommended for routine treatment of guttate psoriasis. (See",
"      <a class=\"local\" href=\"#H1391875286\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/1\">",
"      Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/2\">",
"      Rigopoulos D, Gregoriou S, Katrinaki A, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate. Eur J Dermatol 2010; 20:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/3\">",
"      Kundakci N, T&uuml;rsen U, Babiker MO, G&uuml;rgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/4\">",
"      Valenzuela F, Silva P, Vald&eacute;s MP, Papp K. Epidemiology and quality of life of patients with psoriasis in Chile. Actas Dermosifiliogr 2011; 102:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/5\">",
"      Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007; 87:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/6\">",
"      Kwon HH, Na SJ, Jo SJ, Youn JI. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol 2012; 39:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/7\">",
"      Ko HC, Jwa SW, Song M, et al. Clinical course of guttate psoriasis: long-term follow-up study. J Dermatol 2010; 37:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/8\">",
"      Ferr&aacute;ndiz C, Pujol RM, Garc&iacute;a-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/9\">",
"      Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol 2012; 51:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/10\">",
"      Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol 1997; 109:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/11\">",
"      Wu D, Wu Y, Liu JL, et al. Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis. Genet Mol Res 2011; 10:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/12\">",
"      Holm SJ, Sakuraba K, Mallbris L, et al. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol 2005; 125:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/13\">",
"      Mallbris L, Wolk K, S&aacute;nchez F, St&aring;hle M. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study. BMC Dermatol 2009; 9:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/14\">",
"      Gudjonsson JE, Karason A, Runarsdottir EH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/15\">",
"      Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol 2000; 143:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/16\">",
"      Gudj&oacute;nsson JE, K&aacute;rason A, Antonsd&oacute;ttir AA, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/17\">",
"      NORRLIND R. Psoriasis following infections with hemolytic streptococci. Acta Derm Venereol 1950; 30:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/18\">",
"      Prinz JC. Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/19\">",
"      Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/20\">",
"      Mallbris L, Larsson P, Bergqvist S, et al. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005; 124:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/21\">",
"      Patrizi A, Costa AM, Fiorillo L, Neri I. Perianal streptococcal dermatitis associated with guttate psoriasis and/or balanoposthitis: a study of five cases. Pediatr Dermatol 1994; 11:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/22\">",
"      Herbst RA, Hoch O, Kapp A, Weiss J. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol 2000; 42:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/23\">",
"      Veraldi S, Lunardon L, Dassoni F. Guttate psoriasis triggered by chickenpox. G Ital Dermatol Venereol 2009; 144:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/24\">",
"      Ito T, Furukawa F. Psoriasis guttate acuta triggered by varicella zoster virus infection. Eur J Dermatol 2000; 10:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/25\">",
"      Elewski B. Does pityrosporum ovale have a role in psoriasis? Arch Dermatol 1990; 126:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/26\">",
"      Sandhu K, Jain R, Kaur I, Kumar B. Role of Pityrosporum ovale in guttate psoriasis. J Dermatol 2003; 30:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/27\">",
"      Horner KL, Chien AJ, Edenholm M, Hornung RL. Winnie the Pooh and psoriasis too: an isomorphic response of guttate psoriasis in a tattoo. Pediatr Dermatol 2007; 24:E70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/28\">",
"      Guerra I, Algaba A, P&eacute;rez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012; 6:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/29\">",
"      Brigant F, Clavel G, Chatelain D, et al. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept. Dermatol Online J 2011; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/30\">",
"      Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/31\">",
"      Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-&alpha; inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol 2010; 32:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/32\">",
"      Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, et al. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis 2008; 14:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/33\">",
"      Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, et al. Psoriasis--as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009; 30:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/34\">",
"      Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004; 138:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/35\">",
"      Christophers E, Kiene P. Guttate and plaque psoriasis. Dermatol Clin 1995; 13:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/36\">",
"      Krishnamurthy K, Walker A, Gropper CA, Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol 2010; 9:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/37\">",
"      Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 1996; 132:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/38\">",
"      Williams RC, McKenzie AW, Roger JH, Joysey VC. HL-A antigens in patients with guttate psoriasis. Br J Dermatol 1976; 95:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/39\">",
"      Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. Br J Dermatol 2001; 145:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/40\">",
"      Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. Interventions for guttate psoriasis. Cochrane Database Syst Rev 2000; :CD001213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/41\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/42\">",
"      Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011; 64:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/43\">",
"      Walters IB, Burack LH, Coven TR, et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/44\">",
"      Kirke SM, Lowder S, Lloyd JJ, et al. A randomized comparison of selective broadband UVB and narrowband UVB in the treatment of psoriasis. J Invest Dermatol 2007; 127:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/45\">",
"      Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006; 142:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/46\">",
"      G&ouml;kdemir G, Kivan&ccedil;-Altunay I, K&ouml;??l&uuml; A. Narrow-band ultraviolet B phototherapy in patients with psoriasis: for which types of psoriasis is it more effective? J Dermatol 2005; 32:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/47\">",
"      Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; :CD005028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/48\">",
"      Wilson JK, Al-Suwaidan SN, Krowchuk D, Feldman SR. Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol 2003; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/49\">",
"      Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol 2001; 145:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/50\">",
"      Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev 2000; :CD001976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/51\">",
"      Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol Allied Sci 1996; 21:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/52\">",
"      Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. Preliminary report. J Am Acad Dermatol 1986; 14:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/53\">",
"      Polat M, Lenk N, Yalcin B, et al. Efficacy of erythromycin for psoriasis vulgaris. Clin Exp Dermatol 2007; 32:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/54\">",
"      Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 2000; 27:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/55\">",
"      Tsankov N, Grozdev I. Rifampicin in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2009; 23:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32216/abstract/56\">",
"      Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992; 26:458.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15280 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32216=[""].join("\n");
var outline_f31_29_32216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2503181\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391875244\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391875258\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2500968\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500143\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500010\">",
"      Streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500017\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500846\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391875265\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2499966\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391875279\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500097\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500854\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500104\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2501744\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1391875286\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500863\">",
"      First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2500111\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2500118\">",
"      - Topical corticosteroids and vitamin D analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2500909\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2500132\">",
"      - Tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2502831\">",
"      - Systemic psoriasis therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H716080\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2501654\">",
"      - Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2503181\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15280\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15280|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/9/24725\" title=\"picture 1A\">",
"      Guttate psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/28/42433\" title=\"picture 1B\">",
"      Guttate psoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/6/13414\" title=\"picture 2A\">",
"      Pityriasis rosea dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/20/22852\" title=\"picture 2B\">",
"      Pityriasis rosea trailing scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/61/35793\" title=\"picture 2C\">",
"      Pityriasis rosea with herald patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/24/20865\" title=\"picture 3A\">",
"      Tinea corporis - multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/37/7765\" title=\"picture 3B\">",
"      Tinea corporis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/22/12642\" title=\"picture 4A\">",
"      Papular secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/6/6242\" title=\"picture 4B\">",
"      Palmar rash secondary syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/50/19233\" title=\"picture 5\">",
"      Pityriasis lichenoides chronica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/8/11394\" title=\"picture 6A\">",
"      Nummular eczema legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/46/38626\" title=\"picture 6B\">",
"      Nummular eczema legs 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/33/33301\" title=\"picture 7A\">",
"      Viral exanthem close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/6/37985\" title=\"picture 7B\">",
"      Morbilliform drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15280|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/35/18999?source=related_link\">",
"      Pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/38/6761?source=related_link\">",
"      Tonsillectomy in adults: Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_29_32217="Treatment of early (stage I and II) head and neck cancer: The oral cavity";
var content_f31_29_32217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of early (stage I and II) head and neck cancer: The oral cavity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Neil D Gross, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Nancy Y Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Scott Okuno, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Shyam SD Rao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32217/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/29/32217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma is the predominant malignancy that occurs in the oral cavity. Minor salivary gland cancers and sarcomas are less common.",
"   </p>",
"   <p>",
"    The treatment of early stage oral cavity cancer is presented here. The management of locally advanced oral cavity cancer and the treatment of metastatic and recurrent cancers are discussed separately, as are other types of oral cavity tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1321?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28313?source=see_link\">",
"       \"Salivary gland tumors: Treatment of locoregional disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link\">",
"       \"Head and neck sarcomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88481214\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are an estimated 263,000 cases of oral cavity cancer worldwide each year, which cause about 127,000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/1\">",
"     1",
"    </a>",
"    ]. Oral cavity tumors often present with local invasion, tissue destruction, and lymph node metastases, but they rarely have distant metastases at the time of presentation.",
"   </p>",
"   <p>",
"    Tobacco smoking and alcohol use are the principal risk factors for developing oral cavity squamous cell carcinoma in the western world. The chewing of betel nut quid is a significant factor throughout Asia and India. Oral tobacco use, periodontal disease, radiation, and immune deficiency have also been implicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Sun exposure (ultraviolet radiation) is an important etiologic factor for squamous cell cancer involving the lip, and oral tobacco and betel nut quid chewing are important risk factors for buccal mucosa cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human papillomavirus (HPV) infection is associated with the rising incidence of tonsil and base of tongue cancer in younger adults. These HPV associated tumors do not typically arise in the oral tongue or elsewhere in the oral cavity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity extends from the skin-vermilion junction of the lips to the junction of the hard and soft palate above and to the line of circumvallate papilla of the tongue below. The anterior tonsillar pillars and glossotonsillar folds serve as the lateral boundaries between the oral cavity and oropharynx.",
"   </p>",
"   <p>",
"    Sites of origin of oral cavity cancer include the lip, floor of the mouth, oral tongue (anterior two-thirds of the tongue), lower alveolar ridge, upper alveolar ridge, retromolar trigone (retromolar gingiva), hard palate, and buccal mucosa (",
"    <a class=\"graphic graphic_figure graphicRef54845 \" href=\"mobipreview.htm?3/27/3509\">",
"     figure 1",
"    </a>",
"    ). Rarely, an oral cavity cancer can originate within the mandible (eg, osteosarcoma.) Most odontogenic lesions, including ameloblastoma, are not malignant.",
"   </p>",
"   <p>",
"    The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify lip and oral cavity carcinoma (",
"    <a class=\"graphic graphic_table graphicRef70195 \" href=\"mobipreview.htm?38/12/39117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/6\">",
"     6",
"    </a>",
"    ]. By definition, patients with early (stage I and II) disease have tumors &lt;4 cm in greatest dimension without deep invasion into surrounding structures and have no evidence of lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PRIMARY TUMOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88481456\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor size, the extent or depth of invasion, and the presence or absence of regional lymph node metastases are critical for planning treatment. The depth of invasion of early stage squamous cell carcinoma involving the oral tongue is particularly difficult to assess preoperatively. Oral cavity cancers tend to invade bone and soft tissue early in their natural history. Therefore, pretreatment imaging studies are required in addition to a thorough inspection and palpation of the oral cavity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Computed tomography (CT) with intravenous contrast is widely used to detect bone invasion; CT has largely replaced older techniques such as plain radiography and panoramic radiography of the maxilla and mandible.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) may complement or replace CT scanning by providing better visualization of soft tissue involvement and gross perineural spread, while also having good accuracy in detecting bone invasion. Whereas CT scanning may be limited by metallic dental restorations and cortical defects, MRI is limited by motion artifact and inflammatory reactions.",
"     </li>",
"     <li>",
"      Combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      scans may add accuracy in evaluating the extent of the primary tumor and aid in target delineation if definitive radiation therapy (RT) is being considered. PET scanning may help to identify pathologically involved lymph nodes that are suspicious on CT or MRI but do not meet traditional size based criteria for classification as being abnormal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Surgery versus radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both primary surgery and definitive radiation therapy (RT) are options for patients with oral cavity cancer. Outcomes with primary surgery and definitive RT appear to be similar based upon retrospective studies, but the two modalities have not been compared in randomized trials.",
"   </p>",
"   <p>",
"    Surgery is generally preferred because it is typically associated with less morbidity than RT. Definitive RT is reserved for patients who cannot tolerate surgery or for whom surgical resection would result in particularly severe functional impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The latter circumstance is uncommon in stage I and II oral tongue and floor of mouth primaries but is sometimes applicable to early tumors of the retromolar trigone since external RT can achieve similar outcomes to surgery with acceptable morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional surgical approaches are generally used for patients with early stage oral cavity cancer. Although minimally invasive surgery, such as transoral laser resection or robotic surgery, has been used, the relative advantages of one versus another surgical technique have not been well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The primary benefit of minimally invasive technology is its ability to access structures, such as the oropharynx and larynx, which are not easily approached with standard instruments. However, early stage oral cavity tumors are usually accessible via traditional transoral approaches.",
"   </p>",
"   <p>",
"    Most early stage oral cavity cancers can be excised with minimal long-term functional or cosmetic deformity. Swallowing function is generally excellent with appropriate reconstruction and postoperative rehabilitation. Likewise, short-term perturbations in speech (eg, difficulty pronouncing the letter &ldquo;t&rdquo; after tongue surgery) can be corrected to normal or near-normal function. As an example, an oral cavity cancer patient employed in telephone sales would generally be expected to be able to return to full-time work within three months of surgery.",
"   </p>",
"   <p>",
"    Every attempt should be made to ensure negative resection margins, since positive margins are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. If feasible, reresection of any positive margin is preferred. Otherwise, postoperative RT, with or without chemotherapy, is indicated. Close margins, typically defined as less than 5 mm, may also portend a worse prognosis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Adjuvant therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Acute surgical complications can include infection, bleeding, aspiration, wound breakdown, flap loss, and fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/14\">",
"     14",
"    </a>",
"    ]. Surgical procedures such as hemiglossectomy, maxillectomy, and mandibulotomy can cause functional defects in speech and swallowing, although these may be minimized by optimal reconstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both external beam RT, using contemporary conformal techniques, and brachytherapy can have a role in the management of early stage oral cavity cancer. The general principles of RT and the role of radiation dose and schedule are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small tumors in most oral cavity sites can be managed with intraoral cone or interstitial brachytherapy in order to minimize exposure of normal tissue. These techniques do not treat regional lymph node basins, however, and are therefore only appropriate to use as a single modality in selected stage I patients where the risk of occult nodal involvement is very low. Factors associated with high risk disease of lymph node involvement include deep invasion, and lymphovascular invasion. &nbsp;",
"   </p>",
"   <p>",
"    External beam RT is used as the primary mode of irradiation when regional lymph nodes are at significant risk for subclinical involvement, and intraoral cone-beam radiation or interstitial brachytherapy may be added as a boost to the primary tumor.",
"   </p>",
"   <p>",
"    Significant acute RT toxicities include mucositis, skin reaction, loss of taste, and dysphagia. Late complications may include skin and soft tissue atrophy and fibrosis, osteoradionecrosis (particularly with brachytherapy), lymphedema, and trismus. Xerostomia commonly occurs during the course of RT and persists after treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Xerostomia may recover after treatment with modern RT techniques such as 3D conformal or intensity-modulated radiation therapy (IMRT). However, recovery of xerostomia in patients with oral cavity tumors may be more limited than with other head and neck sites because of higher doses of radiation to the submandibular glands and larger volumes of oral mucosa and minor salivary glands in the treatment fields. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=see_link&amp;anchor=H722454159#H722454159\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\", section on 'Highly conformal RT technique'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88481623\">",
"    <span class=\"h2\">",
"     Specific tumor sites",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both squamous cell and basal cell carcinomas can arise in the lip. Together, these account for about one-fourth of oral cavity cancer. Lip cancers are technically considered part of the oral cavity even though they are often the result of sun exposure and share characteristics with many skin cancers. Surgical excision is generally preferred for management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202278880\">",
"    <span class=\"h4\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and hence prognosis of squamous cell carcinoma of the lip varies depending upon whether the lower or upper lip is involved, and this has implications for management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lower lip",
"      </strong>",
"      &mdash; Squamous cell carcinoma is more common than basal cell carcinoma in the lower lip and has the capacity for lymph node metastasis even at an early stage.",
"      <br/>",
"      <br/>",
"      Maximum tumor thickness is a predictor for metastatic spread to regional lymph nodes for squamous cell carcinoma of the lip and therefore may be important for treatment planning and assessment of prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. In one report of 27 patients with squamous cell carcinoma of the lower lip, there was a significant difference in mean tumor thickness between patients with or without cervical lymph node metastases (5.6 versus 3.8 mm, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/15\">",
"       15",
"      </a>",
"      ]. Whether tumor thickness is independent of tumor stage as a prognostic factor is uncertain.",
"     </li>",
"     <li>",
"      <strong>",
"       Upper lip",
"      </strong>",
"      &mdash; Squamous cell carcinomas that arise in the upper lip and oral commissure have a worse prognosis than those originating in the lower lip. These tumors grow more rapidly, ulcerate sooner, and metastasize earlier (",
"      <a class=\"graphic graphic_picture graphicRef68180 \" href=\"mobipreview.htm?35/58/36771\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73991 \" href=\"mobipreview.htm?3/27/3507\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. Upper lip cancers also have the potential for invasion into the premaxilla and nasal cavity, which can add considerable complexity to the treatment planning and ultimate functional outcome. Therefore, a more aggressive treatment strategy including prophylactic treatment of the neck is generally advocated for even early stage upper lip squamous cell carcinomas. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cosmetic and functional outcomes are important in planning treatment because of the role of the lips in speech, facial expression, and eating. The extent of surgical excision depends entirely upon the size of the lesion. The optimal margin for resection has not been defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], but a margin &ge;5 mm on final pathology is generally recommended.",
"   </p>",
"   <p>",
"    There are numerous reconstructive options to restore function after surgery. Defects that involve less than two-thirds of the lip can be closed primarily, while defects involving up to three-quarters of the lip can be reconstructed with full thickness pedicled flaps from the uninvolved lip (Abbe-Estlander flaps) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/21\">",
"     21",
"    </a>",
"    ]. More complicated reconstructive options are available for larger defects, including the Karapandzic flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mohs micrographic surgery, which is effective for treating early stage skin cancer, has been used to treat early lip cancers but has not been directly compared to standard surgical excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Therefore, we advise caution in treating lip cancer with Mohs surgery, particularly for tumors &gt;2 cm, since narrow margins may be less effective for these tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17400?source=see_link\">",
"     \"Mohs surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the prognosis for early stage squamous cell carcinoma of the lip is very good, with ten-year recurrence-free survival rates of 94 and 78 percent for stage I and II disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H202278901\">",
"    <span class=\"h4\">",
"     Basal cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal cell carcinoma is more common on the upper lip and does not metastasize. The management of basal cell carcinomas is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Floor of mouth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary tumor staging for floor of mouth cancers can be challenging due to difficulties in tumor inspection and measurement. These tumors tend to be locally invasive. There is a high risk of neck lymph node metastases, with occult node metastases reported in 21 and 62 percent of patients with stage I and II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management of the neck'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgery is usually the preferred approach due to the risk of radiation-induced bone necrosis in patients treated with definitive RT. Early stage floor of mouth cancer can generally be managed via transoral excision. Care should be taken to avoid the lingual nerve if oncologically feasible, as this nerve is relatively superficial in the floor of mouth and easily injured.",
"   </p>",
"   <p>",
"    Small to medium defects can be closed primarily, left to close by secondary intention or reconstructed with a skin graft. Large defects are best repaired with a vascularized graft such as a radial forearm free tissue transfer or submental island skin flap to avoid contracture of the tongue and difficulty with speech.",
"   </p>",
"   <p>",
"    Results with definitive RT are similar to those attained with surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Small (&lt;1 cm) or superficial lesions (&lt;4 mm thick) can be treated with either an intraoral cone or interstitial brachytherapy alone. An intraoral cone is more suitable for lesions located centrally or in the anterior part of the mouth. For lesions extending close to or into the tongue, an intraoral stent or bite block helps position the tongue. When a boost is given with an intraoral cone, it is delivered before external beam RT so that mucositis does not impede visualization of the lesion. When a boost is given with interstitial brachytherapy, it is delivered after external beam RT to allow for tumor shrinkage. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Five-year overall survival rates for stage I and II cancers of 95 and 85 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/25,27,28\">",
"     25,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is generally recommended for oral tongue cancer, if good functional rehabilitation can be achieved with reconstruction (",
"    <a class=\"graphic graphic_picture graphicRef57360 \" href=\"mobipreview.htm?16/7/16499\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77425 \" href=\"mobipreview.htm?42/45/43729\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A partial glossectomy with negative margins can preserve speech and swallowing for most stage I and II lesions of the oral tongue. The choice of reconstruction and intensity of rehabilitation determine the ultimate functional outcome (",
"    <a class=\"graphic graphic_picture graphicRef82465 \" href=\"mobipreview.htm?39/49/40721\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessing surgical resection margins can be difficult. Deep tongue muscle margins are not found in a single plane, in contrast to the radial mucosal margins. In addition, striated tongue muscle fibers shred or fragment with tissue handling during and after surgery, leaving a less reliable surface to assess margin status. Therefore, close deep surgical margins should be interpreted with caution and more aggressive treatment may be indicated compared with close radial mucosal margins or close margins in other disease sites.",
"   </p>",
"   <p>",
"    Definitive RT of oral tongue cancer typically combines external beam RT with either an intraoral cone (for tumors less than 2 cm thick) or interstitial brachytherapy for the boost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/32\">",
"     32",
"    </a>",
"    ]. Small (less than or equal to 10 mm) and superficial lesions can be treated with either an intraoral cone or interstitial brachytherapy alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the five-year overall survival for early stage oral tongue cancer reported by a single institution was quite good, 89 and 95 percent for stage I and II cancers, the five-year survival calculated from a population-based database was more modest, 67 and 51 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Tongue cancer is often believed to have a more aggressive course in younger patients (ie, &lt;40 years), but most reports have not found a difference in survival between younger and older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of the neck in patients with early stage cancers of the tongue is controversial. The risk of lymph node metastasis is proportional to depth of invasion. However, preoperative determination of depth of invasion is difficult without a full thickness biopsy, which is rarely done. Distinguishing between patients at low and high risk of lymph node metastasis is variable between surgeons. The decision regarding neck dissection requires a comprehensive assessment of the potential risks and benefits for each early stage oral tongue cancer patient. Patients may have &ldquo;skip metastases&rdquo; with involvement of level III or IV without involvement of levels I and II (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, a selective neck dissection of levels I to IV may be more appropriate than a supraomohyoid dissection of levels I to III. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Management of the neck'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Retromolar trigone and lower alveolar ridge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retromolar trigone is the small mucosal space that begins at the third molar of the mandible and extends posteriorly and cranially to the maxillary tuberosity. It is continuous with the buccal mucosa, upper and lower gingiva, maxillary tuberosity, anterior tonsillar pillar, soft palate, and mouth floor.",
"   </p>",
"   <p>",
"    Even early cancers of the retromolar trigone have a high local recurrence rate due to microscopic extension into the mandible and a high probability of occult regional lymph node metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. The five-year disease-free survival rate for early stage retromolar trigone cancer is about 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical therapy involves wide local excision but resection can be technically challenging. Although small tumors may be managed with a transoral approach, many will require a lip-splitting cheek flap for exposure. Marginal mandibulectomy may be required in order to achieve tumor-free margins.",
"   </p>",
"   <p>",
"    The degree of tumor invasion must be assessed before surgery as well as possible, since this will determine the deep surgical margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/42\">",
"     42",
"    </a>",
"    ]. A planned intraoperative mucosal resection margin of 1 cm is recommended to achieve a final pathologic margin &gt;5 mm since there can be substantial shrinkage of the tumor specimen in formalin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/43\">",
"     43",
"    </a>",
"    ]. In contrast, a deep bone margin of 1 cm is unnecessarily morbid, and instead, a margin of one tissue layer deeper than the greatest depth of invasion is suggested. Preoperative assessment of bone invasion is notoriously difficult and requires considerable experience.",
"   </p>",
"   <p>",
"    Treatment of cancers of the lower alveolar ridge is similar to that for lesions arising in the retromolar trigone. These lesions often have mandibular involvement at presentation.",
"   </p>",
"   <p>",
"    The status of the teeth plays a critical role in treatment of cancers involving the upper and lower alveolar ridge. Many patients with oral cavity cancer are edentulous or have very poor dentition. In these patients, porous cortical bone serves as a poor barrier to invasion and the risk of mandibular invasion is increased even for early stage cancers. Therefore, edentulous patients with even minimal cortical bone invasion should be treated with a segmental resection of bone rather than a marginal resection. In contrast, healthy teeth are a better barrier to direct tumor invasion into the medullary space of the bone and patients with healthy teeth with an intact dental ligament and early stage cancers rarely have mandibular invasion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Upper alveolar ridge and hard palate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both surgery and RT offer excellent control for early stage squamous cell cancers of the upper alveolar ridge and hard palate. However, surgery is generally preferred, because of the late effects of radiation including osteoradionecrosis of the maxilla. Except for the most superficial cancers, surgery usually involves resection of bone including alveolectomy, palatectomy, or infrastructure maxillectomy (ie, resection of the palatine process of the maxillary bone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/34\">",
"     34",
"    </a>",
"    ]. The resulting surgical defects may be closed with local mucosal rotation flaps or free tissue transfer reconstruction for larger defects. However, some surgeons prefer prosthetic rehabilitation with a removable palatal obturator, which permits better inspection of the defect for disease recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=see_link\">",
"     \"Management of acquired maxillary defects: Prosthetic rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Buccal mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Buccal mucosa cancers are often neglected or misdiagnosed as an infection or consequence of trauma, and thus rarely present as T1 lesions. For patients who are diagnosed with early stage buccal mucosa tumors, three-year disease-free-survival rates of 75 to 85 percent for stage I and 65 percent for stage II cancers have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery is typically preferred for buccal mucosa cancers, despite high local recurrence rates and technical challenges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/48\">",
"     48",
"    </a>",
"    ]. Early stage buccal mucosa cancers may appear easy to treat (",
"    <a class=\"graphic graphic_picture graphicRef69202 \" href=\"mobipreview.htm?0/26/421\">",
"     picture 6",
"    </a>",
"    ). However, exposure of the cancer can be difficult via a transoral approach, which makes it difficult to obtain clear radial margins in an en bloc fashion. Furthermore, the short distance between the buccal mucosa and the buccal space permits early invasion to deep structures or to the skin of the anterior cheek. The surgeon must choose between taking a thin deep margin and risking recurrence versus removing skin and reconstructing both the inner and outer cheek surfaces. Although more aggressive surgery, including exenteration of the buccal space and parotidectomy, may improve oncologic results, the disfigurement and morbidity associated with these procedures is considerable (",
"    <a class=\"graphic graphic_picture graphicRef69202 \" href=\"mobipreview.htm?0/26/421\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The buccal mucosal surface must be reconstructed regardless of the depth of resection; inadequate soft tissue coverage will result in severe, irreversible trismus. Thus, free tissue transfer reconstruction (eg, radial forearm flap) is recommended for all but the smallest buccal cancers. In these cases, skin graft reconstruction will suffice. Even with adequate reconstruction, jaw exercises are required for the best functional outcome.",
"   </p>",
"   <p>",
"    Postoperative radiation or chemoradiation is often necessary to maximize the likelihood of locoregional control. If RT is used, the initial treatment volume includes the primary tumor with at least 2 cm margins. An intraoral stent may be used to displace the tongue medially to reduce the dose delivered to this organ. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Radiation therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective treatment of the neck in patients with clinically N0 stage I and II oral cavity cancer remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of occult metastasis as high as 45 percent are found in patients with early stage oral cavity cancer, particularly for cancers of the oral tongue and floor of mouth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/25,50-53\">",
"     25,50-53",
"    </a>",
"    ]. Due to this, an elective neck dissection is generally recommended for patients with stage II disease to reduce the chance of regional recurrences.",
"   </p>",
"   <p>",
"    The indications for an elective neck dissection in patients with stage I disease are controversial, since the incidence of occult metastases for T1 tumors is generally less than 15 to 20 percent. Some clinicians use a threshold of &gt;10 percent for performing elective node dissection while others do not. Other clinical and histologic factors have been investigated to help determine which patients are at highest risk to develop regional lymph node disease.",
"   </p>",
"   <p>",
"    Tumor thickness may be a useful parameter for predicting occult metastases in squamous cell carcinoma, particularly for tumors arising in the tongue. The definition and measurement of tumor thickness or depth of invasion has varied between studies. However, most reports have found that tumor thickness greater than 2 to 4 mm is associated with the presence of occult metastases and reduced recurrence-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a series of 216 patients with early oral tongue cancer, 91 percent of patients with a depth of invasion &lt;2 mm were pathologically N0, compared to 73 percent of those with a depth of invasion &ge;2 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninvasive techniques to assess tumor thickness (clinical palpation, CT, PET, MRI, intraoral ultrasonography, and frozen section analysis) all have limitations. Thus, the thickness of the primary tumor is generally unknown prior to an elective neck dissection unless a two-stage procedure is planned. As a consequence, many experienced head and neck surgeons adopt a \"thick\" versus \"thin\" strategy and will defer elective neck dissection for only the most superficial cancers.",
"   </p>",
"   <p>",
"    The optimal extent of neck dissection is uncertain; limiting the extent of dissection reduces the morbidity. A supraomohyoid neck dissection that includes levels I to III is typically sufficient for clinically N0 oral cavity cancer since level IV and V lymph nodes are rarely involved without clinical disease at other levels (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/35,57-59\">",
"     35,57-59",
"    </a>",
"    ]. This approach includes removal of the submandibular gland but preserves the spinal accessory nerve, the internal jugular vein, and the sternocleidomastoid muscle. Sublevel IIB may also be preserved in patients with early stage oral cavity cancer, thus minimizing the risk of shoulder dysfunction from damage to the spinal accessory nerve, which runs through sublevel IIB. One exception to this approach is oral tongue cancer, which may develop skip metastases to level IV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with oral cavity cancer, we generally recommend an ipsilateral selective neck dissection, levels I to",
"    <span class=\"nowrap\">",
"     III/IV,",
"    </span>",
"    for stage I cancers with greater than 2 mm of invasion and all stage II disease. Levels IIB and IV are dissected at the discretion of the surgeon. Level V dissection is usually unnecessary. Patients with primary tumors close to or involving the midline should be managed with bilateral neck dissection.",
"   </p>",
"   <p>",
"    More specific recommendations, incorporating the primary tumor site, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elective neck treatment is usually not performed for T1 lower lip cancers. For T2 and larger cancers, elective dissection can be limited to levels IA and 1B (suprahyoid dissection) since lower lip cancers usually do not metastasize to lower cervical nodes without first invading facial, submental and submandibular lymph nodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For all T1 and T2 oral tongue cancers with &ge;2 mm depth of invasion, we suggest an elective lymph node dissection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/61-64\">",
"       61-64",
"      </a>",
"      ]. There is no consensus on what levels of lymph node dissection are appropriate for high risk T1 or T2 oral cavity cancers.",
"     </li>",
"     <li>",
"      For all lower alveolar ridge and retromolar trigone cancers, regardless of size, we suggest elective neck dissection, including levels I to III, given the particularly high incidence of occult nodal metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For early stage cancers of the upper alveolar ridge and hard palate the incidence of occult cervical lymph node metastases is low; therefore, elective treatment of the neck is usually not indicated.",
"     </li>",
"     <li>",
"      For buccal mucosa cancers, the facial lymph nodes adjacent to the facial artery and vein at the mandibular ramus are at high risk of metastasis, and particular attention should be paid to this area during an elective neck dissection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients whose primary treatment is RT, elective irradiation of the neck follows the same indications as for elective neck dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant postoperative radiation, with or without concurrent chemotherapy, is indicated for patients who have positive or close final resection margins (if not re-resected), bone invasion, or pathologically positive lymph nodes. Postoperative RT should also be considered if there is lymphovascular or perineural invasion in the primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contemporary conformal RT techniques should be used to minimize treatment-related morbidity, particularly late xerostomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32217/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence to support the use of chemotherapy for early-stage oral cavity cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of head and neck cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur within this timeframe. Continued follow-up beyond five years is generally suggested because of the risk of late recurrence and for second primary malignancies. Due to the higher risk of recurrence and second primary malignancy in those who continue tobacco use, many schedule more frequent surveillance visits and continue for longer duration (ie, beyond five years) for patients who continue tobacco use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/38/5731?source=see_link\">",
"       \"Patient information: Tongue cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cavity squamous cell carcinomas include tumors that originate in the lip, floor of the mouth, oral tongue, lower alveolar ridge, upper alveolar ridge, retromolar trigone, hard palate, and buccal mucosa. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients, we suggest primary surgery rather than definitive radiation therapy (RT) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Definitive RT represents an alternative for select patients, but because of its increased morbidity, we believe that RT should be used primarily when primary surgery is not feasible. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgery versus radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with close or positive margins of resection, we suggest re-resection rather than postoperative RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For close or positive margins that are not re-resected, as well as for occult bone involvement and lymphovascular or perineural invasion, we suggest postoperative RT with or without concurrent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with stage I oral tongue cancers and stage II oral cavity cancers at other sites (",
"      <a class=\"graphic graphic_table graphicRef70195 \" href=\"mobipreview.htm?38/12/39117\">",
"       table 1",
"      </a>",
"      ), we recommend elective treatment of the neck (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An ipsilateral selective neck dissection, levels I to III, is generally sufficient (",
"      <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"       figure 2",
"      </a>",
"      ). Patients with primary tumors close to or involving the midline should be managed with bilateral neck dissection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Globocan file://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (Accessed on June 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/2\">",
"      Moore S, Johnson N, Pierce A, Wilson D. The epidemiology of lip cancer: a review of global incidence and aetiology. Oral Dis 1999; 5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/3\">",
"      King GN, Healy CM, Glover MT, et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 1995; 332:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/4\">",
"      Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/5\">",
"      Chen YK, Huang HC, Lin LM, Lin CC. Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncol 1999; 35:173.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/8\">",
"      Sykes AJ, Allan E, Irwin C. Squamous cell carcinoma of the lip: the role of electron treatment. Clin Oncol (R Coll Radiol) 1996; 8:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/9\">",
"      de Visscher JG, Grond AJ, Botke G, van der Waal I. Results of radiotherapy for squamous cell carcinoma of the vermilion border of the lower lip. A retrospective analysis of 108 patients. Radiother Oncol 1996; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/10\">",
"      Boudreaux BA, Rosenthal EL, Magnuson JS, et al. Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg 2009; 135:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/11\">",
"      Eckel HE, Volling P, Pototschnig C, et al. Transoral laser resection with staged discontinuous neck dissection for oral cavity and oropharynx squamous cell carcinoma. Laryngoscope 1995; 105:53.",
"     </a>",
"    </li>",
"    <li>",
"     Standards and minimum datasets for reporting cancers. Dataset for histopathological reports on head and neck carcinomas and salivary neoplasms. In: Royal College of Pathologists Guidelines, 2nd, Helliwell T, Woolgar JA (Eds), Royal College of Pathologists, London 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/13\">",
"      Bradley PJ, MacLennan K, Brakenhoff RH, Leemans CR. Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. Curr Opin Otolaryngol Head Neck Surg 2007; 15:74.",
"     </a>",
"    </li>",
"    <li>",
"     Koch WM, Stafford E, Baja G. Cancer of the oral cavity. In: Head and neck cancer: a multidisciplinary approach, 3rd, Harrison LB, Sessions RB, Hong WK (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. p.250.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/15\">",
"      McCombe D, MacGill K, Ainslie J, et al. Squamous cell carcinoma of the lip: a retrospective review of the Peter MacCallum Cancer Institute experience 1979-88. Aust N Z J Surg 2000; 70:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/16\">",
"      Zitsch RP 3rd, Park CW, Renner GJ, Rea JL. Outcome analysis for lip carcinoma. Otolaryngol Head Neck Surg 1995; 113:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/17\">",
"      Lindqvist C, Teppo L. Is upper lip cancer \"true\" lip cancer? J Cancer Res Clin Oncol 1980; 97:187.",
"     </a>",
"    </li>",
"    <li>",
"     Sharma PK, Sculler DE, Baker SR. Malignant lesions of the oral cavity. In: Otolaryngology Head and Neck Surgery, Cummings CC, Frederickson JM, Harker LA, et al (Eds), Mosby-Year Book, St. Louis 1998. Vol 1444.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/19\">",
"      Zitsch RP 3rd. Carcinoma of the lip. Otolaryngol Clin North Am 1993; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/20\">",
"      Babington S, Veness MJ, Cakir B, et al. Squamous cell carcinoma of the lip: is there a role for adjuvant radiotherapy in improving local control following incomplete or inadequate excision? ANZ J Surg 2003; 73:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/21\">",
"      Coppit GL, Lin DT, Burkey BB. Current concepts in lip reconstruction. Curr Opin Otolaryngol Head Neck Surg 2004; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/22\">",
"      Hanasono MM, Langstein HN. Extended Karapandzic flaps for near-total and total lower lip defects. Plast Reconstr Surg 2011; 127:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/23\">",
"      Holmkvist KA, Roenigk RK. Squamous cell carcinoma of the lip treated with Mohs micrographic surgery: outcome at 5 years. J Am Acad Dermatol 1998; 38:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/24\">",
"      Zide MF, Adnot J. Lower lip cancer: Mohs micrographic surgery and reconstruction as a multidisciplinary effort. J Oral Maxillofac Surg 1997; 55:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/25\">",
"      Hicks WL Jr, Loree TR, Garcia RI, et al. Squamous cell carcinoma of the floor of mouth: a 20-year review. Head Neck 1997; 19:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/26\">",
"      Sessions DG, Spector GJ, Lenox J, et al. Analysis of treatment results for floor-of-mouth cancer. Laryngoscope 2000; 110:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/27\">",
"      Matsumoto S, Takeda M, Shibuya H, Suzuki S. T1 and T2 squamous cell carcinomas of the floor of the mouth: results of brachytherapy mainly using 198Au grains. Int J Radiat Oncol Biol Phys 1996; 34:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/28\">",
"      Rodgers LW Jr, Stringer SP, Mendenhall WM, et al. Management of squamous cell carcinoma of the floor of mouth. Head Neck 1993; 15:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/29\">",
"      Fujita M, Hirokawa Y, Kashiwado K, et al. An analysis of mandibular bone complications in radiotherapy for T1 and T2 carcinoma of the oral tongue. Int J Radiat Oncol Biol Phys 1996; 34:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/30\">",
"      Matsuura K, Hirokawa Y, Fujita M, et al. Treatment results of stage I and II oral tongue cancer with interstitial brachytherapy: maximum tumor thickness is prognostic of nodal metastasis. Int J Radiat Oncol Biol Phys 1998; 40:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/31\">",
"      Hicks WL Jr, North JH Jr, Loree TR, et al. Surgery as a single modality therapy for squamous cell carcinoma of the oral tongue. Am J Otolaryngol 1998; 19:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/32\">",
"      Wendt CD, Peters LJ, Delclos L, et al. Primary radiotherapy in the treatment of stage I and II oral tongue cancers: importance of the proportion of therapy delivered with interstitial therapy. Int J Radiat Oncol Biol Phys 1990; 18:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/33\">",
"      Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer 2008; 112:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/34\">",
"      Truitt TO, Gleich LL, Huntress GP, Gluckman JL. Surgical management of hard palate malignancies. Otolaryngol Head Neck Surg 1999; 121:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/35\">",
"      Byers RM, Weber RS, Andrews T, et al. Frequency and therapeutic implications of \"skip metastases\" in the neck from squamous carcinoma of the oral tongue. Head Neck 1997; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/36\">",
"      Tsue TT, McCulloch TM, Girod DA, et al. Predictors of carcinomatous invasion of the mandible. Head Neck 1994; 16:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/37\">",
"      Hao SP, Tsang NM, Chang KP, et al. Treatment of squamous cell carcinoma of the retromolar trigone. Laryngoscope 2006; 116:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/38\">",
"      Cleary KR, Batsakis JG. Oral squamous cell carcinoma and the mandible. Ann Otol Rhinol Laryngol 1995; 104:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/39\">",
"      Mendenhall WM, Morris CG, Amdur RJ, et al. Retromolar trigone squamous cell carcinoma treated with radiotherapy alone or combined with surgery. Cancer 2005; 103:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/40\">",
"      Byers RM, Newman R, Russell N, Yue A. Results of treatment for squamous carcinoma of the lower gum. Cancer 1981; 47:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/41\">",
"      Huang CJ, Chao KS, Tsai J, et al. Cancer of retromolar trigone: long-term radiation therapy outcome. Head Neck 2001; 23:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/42\">",
"      Lo K, Fletcher GH, Byers RM, et al. Results of irradiation in the squamous cell carcinomas of the anterior faucial pillar-retromolar trigone. Int J Radiat Oncol Biol Phys 1987; 13:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/43\">",
"      Lam KH, Lam LK, Ho CM, Wei WI. Mandibular invasion in carcinoma of the lower alveolus. Am J Otolaryngol 1999; 20:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/44\">",
"      Nair MK, Sankaranarayanan R, Padmanabhan TK. Evaluation of the role of radiotherapy in the management of carcinoma of the buccal mucosa. Cancer 1988; 61:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/45\">",
"      Dixit S, Vyas RK, Toparani RB, et al. Surgery versus surgery and postoperative radiotherapy in squamous cell carcinoma of the buccal mucosa: a comparative study. Ann Surg Oncol 1998; 5:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/46\">",
"      Diaz EM Jr, Holsinger FC, Zuniga ER, et al. Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients. Head Neck 2003; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/47\">",
"      Iyer SG, Pradhan SA, Pai PS, Patil S. Surgical treatment outcomes of localized squamous carcinoma of buccal mucosa. Head Neck 2004; 26:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/48\">",
"      Strome SE, To W, Strawderman M, et al. Squamous cell carcinoma of the buccal mucosa. Otolaryngol Head Neck Surg 1999; 120:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/49\">",
"      Bessell A, Glenny AM, Furness S, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database Syst Rev 2011; :CD006205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/50\">",
"      Duvvuri U, Simental AA Jr, D'Angelo G, et al. Elective neck dissection and survival in patients with squamous cell carcinoma of the oral cavity and oropharynx. Laryngoscope 2004; 114:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/51\">",
"      de Visscher JG, van den Elsaker K, Grond AJ, et al. Surgical treatment of squamous cell carcinoma of the lower lip: evaluation of long-term results and prognostic factors--a retrospective analysis of 184 patients. J Oral Maxillofac Surg 1998; 56:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/52\">",
"      Guney E, Yigitbasi OG. Functional surgical approach to the level I for staging early carcinoma of the lower lip. Otolaryngol Head Neck Surg 2004; 131:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/53\">",
"      Capote A, Escorial V, Mu&ntilde;oz-Guerra MF, et al. Elective neck dissection in early-stage oral squamous cell carcinoma--does it influence recurrence and survival? Head Neck 2007; 29:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/54\">",
"      Pentenero M, Gandolfo S, Carrozzo M. Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: a review of the literature. Head Neck 2005; 27:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/55\">",
"      Huang SH, Hwang D, Lockwood G, et al. Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies. Cancer 2009; 115:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/56\">",
"      Ganly I, Patel S, Shah J. Early stage squamous cell cancer of the oral tongue--clinicopathologic features affecting outcome. Cancer 2012; 118:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/57\">",
"      Dias FL, Lima RA, Kligerman J, et al. Relevance of skip metastases for squamous cell carcinoma of the oral tongue and the floor of the mouth. Otolaryngol Head Neck Surg 2006; 134:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/58\">",
"      Ferlito A, Silver CE, Rinaldo A. Elective management of the neck in oral cavity squamous carcinoma: current concepts supported by prospective studies. Br J Oral Maxillofac Surg 2009; 47:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/59\">",
"      De Cicco C, Trifir&ograve; G, Calabrese L, et al. Lymphatic mapping to tailor selective lymphadenectomy in cN0 tongue carcinoma: beyond the sentinel node concept. Eur J Nucl Med Mol Imaging 2006; 33:900.",
"     </a>",
"    </li>",
"    <li>",
"     Schantz SP, Harrison LB, Forasteriere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Principles and Practice of Oncology, 5th, Devita VT Jr, Hellman S, Rosenberg, SA (Eds), Lippincott-Raven, Philadelphia 1997. p.753.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/61\">",
"      Greenberg JS, El Naggar AK, Mo V, et al. Disparity in pathologic and clinical lymph node staging in oral tongue carcinoma. Implication for therapeutic decision making. Cancer 2003; 98:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/62\">",
"      Haddadin KJ, Soutar DS, Oliver RJ, et al. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head Neck 1999; 21:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/63\">",
"      Byers RM, El-Naggar AK, Lee YY, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue? Head Neck 1998; 20:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/64\">",
"      Kurokawa H, Yamashita Y, Takeda S, et al. Risk factors for late cervical lymph node metastases in patients with stage I or II carcinoma of the tongue. Head Neck 2002; 24:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/65\">",
"      Hinerman RW, Mendenhall WM, Morris CG, et al. Postoperative irradiation for squamous cell carcinoma of the oral cavity: 35-year experience. Head Neck 2004; 26:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32217/abstract/66\">",
"      Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys 2009; 73:1096.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3407 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32217=[""].join("\n");
var outline_f31_29_32217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88481214\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT OF PRIMARY TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88481456\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Surgery versus radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88481623\">",
"      Specific tumor sites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H202278880\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H202278901\">",
"      Basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Floor of mouth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral tongue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Retromolar trigone and lower alveolar ridge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Upper alveolar ridge and hard palate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Buccal mucosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT OF THE NECK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3407|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/27/3509\" title=\"figure 1\">",
"      Anatomy of the oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3407|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/58/36771\" title=\"picture 1\">",
"      T2 upper lip SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/27/3507\" title=\"picture 2\">",
"      Upper lip defect resect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/7/16499\" title=\"picture 3\">",
"      T1 oral tongue SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/45/43729\" title=\"picture 4\">",
"      T2 oral tongue SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/49/40721\" title=\"picture 5\">",
"      Tongue reconstruct STSG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/26/421\" title=\"picture 6\">",
"      Buccal SCC resected",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/12/39117\" title=\"table 1\">",
"      TNM stage oral cavity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/45/8919?source=related_link\">",
"      Management of acquired maxillary defects: Prosthetic rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/63/17400?source=related_link\">",
"      Mohs surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/38/5731?source=related_link\">",
"      Patient information: Tongue cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28313?source=related_link\">",
"      Salivary gland tumors: Treatment of locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1321?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_29_32218="Rett syndrome";
var content_f31_29_32218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rett syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Rebecca J Schultz, PhD, RN, CPNP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Daniel G Glaze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/29/32218/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/29/32218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rett syndrome (RTT) is a neurodevelopmental disorder that occurs almost exclusively in females. It was described in 1966 by Andreas Rett, an Austrian neuropediatrician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/1\">",
"     1",
"    </a>",
"    ]. After a period of initially normal development, affected patients experience loss of speech and purposeful hand use, stereotypic hand movements, and gait abnormalities. Additional features include deceleration of head growth, seizures, autistic features, and breathing abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]. Most cases result from mutations in the MECP2 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review Rett syndrome. Autism spectrum disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=see_link\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link\">",
"     \"Clinical features of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=see_link\">",
"     \"Diagnosis of autism spectrum disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the majority of patients, Rett syndrome (RTT) is caused by mutations in the MECP2 gene, which maps to Xq28 and encodes methyl-CpG binding protein 2 (MeCP2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3\">",
"     3",
"    </a>",
"    ]. Although MeCP2 is expressed in all tissues, it is most abundant in the brain, which may be more sensitive to abnormal MeCP2 than other tissues. A minority of patients have atypical forms or variants of RTT caused by mutations in CDLK5 or FOXG1 genes, though MECP2 mutations are found in some girls with variant RTT. (See",
"    <a class=\"local\" href=\"#H22967440\">",
"     'Defined variant forms of RTT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Three types of MECP2 mutations occur: missense, frameshift, and nonsense. The type of mutation may affect phenotypic expression. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Genotype-phenotype correlations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most individuals with RTT have random X-inactivation (also known as Lyonization) so that the normal allele is expressed in some cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The normal allele appears to enable affected females to survive but does not protect them from neurodevelopmental abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3\">",
"     3",
"    </a>",
"    ]. Random inactivation also contributes to the spectrum of phenotypes in RTT. Except in special circumstances such as Klinefelter syndrome or mosaicism, similar mutations in brothers of affected girls result in severe neonatal encephalopathy and are lethal.",
"   </p>",
"   <p>",
"    Some affected patients have nonrandom X-inactivation. In one series, this was associated with a milder phenotype or a mitigated classic RTT caused by a rare, early truncating mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in MECP2 have been detected in 25 to 100 percent of classic sporadic RTT cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/5-13\">",
"     5-13",
"    </a>",
"    ]: 33 to 58 percent of atypical RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/13-15\">",
"     13-15",
"    </a>",
"    ] and 0 to 30 percent of familial cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. The diagnostic categories of RTT are described below. (See",
"    <a class=\"local\" href=\"#H22967010\">",
"     'Typical and atypical Rett syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Variations in the rates of detected mutations may relate to clinical criteria and exclusion of variants, differences in testing methodology, and abnormalities in noncoding or promoter regions that have not been analyzed.",
"   </p>",
"   <p>",
"    Rett syndrome is sporadic in nearly all cases (&gt;99 percent) and is most often due to de novo mutations in the MECP2 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/16\">",
"     16",
"    </a>",
"    ]. These mutations are almost exclusively of paternal origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/17\">",
"     17",
"    </a>",
"    ]. This may explain the high female to male ratio in RTT and suggests another cause of male sparing besides lethality. In rare familial cases, the mother was either a carrier of the mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3,5,18-21\">",
"     3,5,18-21",
"    </a>",
"    ] or a mosaic for the mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3\">",
"     3",
"    </a>",
"    ]. In one family with affected male children and a female child with classic RTT, the MECP2 mutation was located on the mother's paternal X-chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of the MECP2 gene have also been detected in other neurologic disorders. These include girls with non-Rett phenotypes such as autism, girls and boys with nonspecific X-linked mental retardation, and boys with progressive spasticity, congenital encephalopathy with respiratory arrest, or non-fatal neurodevelopmental disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/18-20,22,23\">",
"     18-20,22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=see_link&amp;anchor=H13#H13\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;How MECP2 mutations lead to RTT is not yet established. MECP2 contains two functional domains, a methyl-CpG binding domain and a transcriptional repression domain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/24\">",
"     24",
"    </a>",
"    ]. One possibility is that interaction between these two domains leads to transcriptional repression of some genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. However, transcriptional profiling analyses have failed to find consistent gene targets that are silenced by MECP2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possibility is that MECP2 normally functions to repress transcription of some parentally imprinted genes. MECP2 mutations might then cause a loss of imprinting with subsequent target gene dysregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=see_link&amp;anchor=H1497302#H1497302\">",
"     \"Basic principles of genetic disease\", section on 'Imprinting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, evidence regarding this hypothesis is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genotype-phenotype correlations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are more than 200 known pathogenic MECP2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/33\">",
"     33",
"    </a>",
"    ]. However, the nine most frequently identified mutations (R106W, R133C, T158M, R168X, R255X, R270X, R294X, R306C, and C-terminal truncations) together account for 78 percent of the MECP2 mutations reported in patients with RTT. As noted above, three types of MECP2 mutations occur: missense, frameshift, and nonsense.",
"   </p>",
"   <p>",
"    Results from earlier and smaller studies of genotype-phenotype correlation in RTT were generally inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/34\">",
"     34",
"    </a>",
"    ]. Data from studies evaluating large databases or series of patients with RTT suggest that the R133C, R294X, and C-terminal truncating mutations are associated with somewhat milder disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Nevertheless, there is variability regarding the severity of the clinical syndrome associated with the different mutations; some studies have reported that the R270X and R255X mutations are associated with more severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], while others have found that the R168X and T158M mutations are generally more severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Although these phenotypic differences can be distinguished among RTT populations, the MECP2 mutations have broadly overlapping phenotypic variability. Thus, their prognostic value for individual patients with RTT is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NEUROPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain growth is differentially affected in RTT. In a postmortem study of 39 patients 3 to 35 years old, most RTT brains were smaller than normal and did not grow after age four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, the heart, kidneys, liver, and spleen grew at a normal rate until 8 to 12 years of age. At that time, their growth rate decelerated but continued so that organ weights were appropriate for height, which was also reduced. Adrenal organ weights were normal.",
"   </p>",
"   <p>",
"    Deceleration of brain growth in RTT begins after birth. The mechanism is uncertain but appears to reflect arrested development. This is supported by morphologic observations that include no evidence of brain degeneration, no alteration in brain weight with increasing age, lack of correlation of dendritic length with increasing age, and reduced neuromelanin in the substantia nigra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/41-46\">",
"     41-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the dendrites of pyramidal neurons were examined in six regions of the cerebral cortex in girls with RTT, ages 2.9 to 35 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/47\">",
"     47",
"    </a>",
"    ]. The cortex was selectively involved. The apical and basilar dendritic branches in layers 3 and 5 of the frontal, motor, and inferior temporal cortex were shorter compared to brains in trisomy 21 or non-Rett neurologic disorders. These findings did not change with age.",
"   </p>",
"   <p>",
"    In other reports, the proteins that initiate cortical dendritic differentiation and expansion (Map2, adult form) and dendritic remodeling (cyclooxygenase) were defectively expressed in RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This indicated marked disruption of a major cytoskeletal component in the cortex. The relationship of these findings with the MECP2 mutation is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33403553\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report from a large population-based registry in Texas, the prevalence of classic RTT was estimated as one per 22,800 females ages 2 through 18 years, or 0.44 per 10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/50\">",
"     50",
"    </a>",
"    ]. The prevalence per 10,000 girls was 0.56 in France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/51\">",
"     51",
"    </a>",
"    ], 0.65 in Sweden and Scotland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], and 0.72 in Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/54\">",
"     54",
"    </a>",
"    ]. RTT occurs in all ethnic and racial groups, and at similar rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/50,55\">",
"     50,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical picture of typical (classic) RTT is unique. Affected patients initially develop normally and then experience loss of speech and purposeful hand use and onset of stereotypic hand movement and gait abnormalities. Additional manifestations can include deceleration of head growth, seizures, autistic features, and intermittent breathing abnormalities.",
"   </p>",
"   <p>",
"    Girls with classic RTT are typically born at term after an uneventful pregnancy and delivery. They usually appear developmentally normal for the first six months with no gross abnormalities (",
"    <a class=\"graphic graphic_picture graphicRef53558 \" href=\"mobipreview.htm?39/33/40479\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76864 \" href=\"mobipreview.htm?43/27/44479\">",
"     picture 2",
"    </a>",
"    ). Although some nonspecific signs may be present during the first six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], no clinically significant developmental problems typically appear during that time other than deceleration of head growth.",
"   </p>",
"   <p>",
"    Deceleration of head growth beginning as early as two to three months of age is often the first sign of RTT although this feature is not present in all individuals with typical RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/58\">",
"     58",
"    </a>",
"    ] and is no longer considered one of the necessary criteria for RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]. At 12 to 18 months, loss of acquired fine motor, intellectual, and communicative abilities is seen (",
"    <a class=\"graphic graphic_picture graphicRef65333 \" href=\"mobipreview.htm?37/49/38673\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56128 \" href=\"mobipreview.htm?25/6/25697\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/59\">",
"     59",
"    </a>",
"    ]. In some cases, this regression is rapid, with parents reporting \"She woke up and was no longer speaking.\" In others, regression is slow and insidious, occurring over weeks to months with diminished interest in the surroundings and loss of purposeful hand use. During this phase, unprovoked episodes of inconsolable screaming may occur during the day or at night, disrupting sleep. These begin abruptly, may last for hours, and often provoke an exhaustive evaluation for other medical conditions if RTT has not yet been diagnosed.",
"   </p>",
"   <p>",
"    In the beginning of the regression phase, stereotypic hand movements may be subtle and interspersed with purposeful hand use. They typically consist of periodic hand-to-mouth licking or grasping of the hair or clothing. Each girl develops her own distinctive unique hand pattern (",
"    <a class=\"graphic graphic_picture graphicRef67899 \" href=\"mobipreview.htm?41/21/42320\">",
"     picture 5",
"    </a>",
"    ). Some retain the ability to hold a cup or feed themselves in a messy, rudimentary manner.",
"   </p>",
"   <p>",
"    Following the regression phase, there is a period of some recovery of nonverbal communication, with improved eye contact and nonverbal interactions with the environment. This is followed by a slow, insidious deterioration in gross motor function. Additional features that occur in the majority of patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Growth failure",
"     </li>",
"     <li>",
"      Epilepsy",
"     </li>",
"     <li>",
"      Disorganized breathing pattern during wakefulness characterized by periods of apnea alternating with periods of hyperventilation",
"     </li>",
"     <li>",
"      Autonomic nervous system dysfunction, characterized by cold feet and peripheral vasomotor disturbances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other serious conditions associated with RTT include cardiac abnormalities that may lead to sudden death, motor dysfunction, scoliosis, and sleep disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107356647\">",
"    <span class=\"h2\">",
"     Loss of spoken language",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of girls with RTT lose expressive language, although some may retain one-word expressions. They appear to communicate via eye gaze, body language, and facial expressions. However, it is often difficult to measure these behaviors using standardized instruments. A systematic review of eight studies that included 41 females with RTT (age 2 to 36 years) found some evidence of communicative behaviors for at least some girls in each included study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/60\">",
"     60",
"    </a>",
"    ]. However, the authors concluded that the validity of these findings is unknown, in part because of the lack of valid measuring tools to assess communication in subjects with impairments as severe as those found in girls with RTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107358573\">",
"    <span class=\"h2\">",
"     Motor dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrapyramidal motor dysfunction with stereotypic hand movements and gait disturbance affects all patients with RTT. Stereotypic hand movements include opposition of hands, finger kneading and rubbing, hand clapping and washing, wringing, squeezing, twisting, and pill rolling (",
"    <a class=\"graphic graphic_picture graphicRef67899 \" href=\"mobipreview.htm?41/21/42320\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/61\">",
"     61",
"    </a>",
"    ]. The gait typically is broad-based, clumsy, and",
"    <span class=\"nowrap\">",
"     ataxic/apraxic",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/1,59\">",
"     1,59",
"    </a>",
"    ]. Patients often have retropulsion and rock to and fro while standing or sitting. Many have difficulty crossing from one floor surface or color to another and will stop and refuse to take another step.",
"   </p>",
"   <p>",
"    Extrapyramidal motor disturbances were characterized in a series of 32 affected patients, ages 30 months to 28 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/62\">",
"     62",
"    </a>",
"    ]. Abnormalities identified in addition to stereotypic movements and gait disturbance included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bruxism &mdash; 97 percent",
"     </li>",
"     <li>",
"      Oculogyric crises &mdash; 63 percent",
"     </li>",
"     <li>",
"      Dystonia &mdash; 59 percent",
"     </li>",
"     <li>",
"      Proximal myoclonus &mdash; 34 percent",
"     </li>",
"     <li>",
"      Excessive drooling &mdash; 75 percent",
"     </li>",
"     <li>",
"      Rigidity &mdash; 44 percent",
"     </li>",
"     <li>",
"      Bradykinesia &mdash; 41 percent",
"     </li>",
"     <li>",
"      Hypomimia &mdash; 63 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying mechanism for these extrapyramidal disturbances is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107358580\">",
"    <span class=\"h3\">",
"     Scoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis is common in RTT and increases with age. By age 16, the prevalence of scoliosis in patients with RTT ranges from 50 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Factors that are associated with scoliosis include delayed, lost, or absent walking, higher clinical severity scores, and constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. In addition, the risk for developing scoliosis may vary with genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In an analysis of a large RTT database, the risk of scoliosis (after adjusting for age and other clinical parameters) was significantly decreased for the R294X and R306C mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884434\">",
"    <span class=\"h2\">",
"     Growth failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic growth pattern of RTT consists of early deceleration of head growth, followed by deceleration of weight and height measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/67\">",
"     67",
"    </a>",
"    ]. This pattern of head growth deviates from growth aberrations associated with chronic disease or central nervous system or chromosomal disorders while the deceleration in ponderal growth is similar to patterns seen with acute and chronic malnutrition. Deceleration in head growth may provide the earliest clinical indicator for the diagnosis of RTT, but is not required for the clinical diagnosis.",
"   </p>",
"   <p>",
"    In a longitudinal study of growth in 816 girls with RTT, including 726 with typical (classic) RTT and 90 with atypical RTT, the following observations were noted for growth in typical RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean head circumference decreased below that of the normative population at one month. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H13#H13\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'Evaluation of growth'",
"      </a>",
"      .) By age two years, mean head circumference was two standard deviations below normal.",
"     </li>",
"     <li>",
"      Mean weight fell below normal by age 13 months, and declined to the second percentile at age 12.5 years.",
"     </li>",
"     <li>",
"      Mean height decreased below normal by age 17 months, and was two standard deviations below normal by age 12 years. However, the distribution of height in classic RTT was wide, and height above the 98",
"      <sup>",
"       th",
"      </sup>",
"      percentile was observed in approximately 8 percent of girls with RTT.",
"     </li>",
"     <li>",
"      Pubertal increases in height and weight were attenuated",
"     </li>",
"     <li>",
"      Poor growth was associated with greater disease severity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five patterns of growth were discerned in typical RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe somatic growth failure with microcephaly (33 percent)",
"     </li>",
"     <li>",
"      Normal somatic growth with microcephaly (30 percent)",
"     </li>",
"     <li>",
"      Moderate somatic growth failure with microcephaly (19 percent)",
"     </li>",
"     <li>",
"      Normal growth (14 percent)",
"     </li>",
"     <li>",
"      Moderate somatic growth failure with normal head size (3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with typical RTT, a greater proportion of patients with atypical RTT had normal growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, girls with RTT had slower rates of hand and foot growth than normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/68\">",
"     68",
"    </a>",
"    ]. Relative to height, the rate of decelerated growth was greater for feet than hands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884441\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although multiple factors are likely responsible for the growth aberration in RTT, inadequate nutrition appears to play an important role. This may result from inadequate dietary intake, alterations in energy expenditure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feeding difficulties.",
"   </p>",
"   <p>",
"    The contribution of increased energy expenditure due to involuntary repetitive movements is uncertain. In one study, total daily energy expenditure adjusted for differences in body weight was similar in RTT and healthy girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/69\">",
"     69",
"    </a>",
"    ]. In another study from the same group, metabolic rates while sleeping and quietly awake were 23 percent lower in girls with RTT than controls; rates while actively awake were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/70\">",
"     70",
"    </a>",
"    ]. Although total daily energy expenditure was similar in the two groups, energy balance was less positive in the girls with RTT than controls. If sustained, these small deficits in energy balance may account for growth failure.",
"   </p>",
"   <p>",
"    Aggressive nutritional support improves growth in RTT, confirming the importance of dietary energy intake. In a preliminary report, an aggressive nutritional intervention was made in girls with RTT using gastrostomy feedings in amounts that approximated an energy intake of 85",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/71\">",
"     71",
"    </a>",
"    ]. During one year, the velocity for height and weight increased by 33 percent and 10-fold, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/71\">",
"     71",
"    </a>",
"    ]. However, the weight gain consisted of 63 percent fat and only 37 percent lean body mass. This deficit in lean body mass deposition may be explained by a defect in body protein metabolism. In another preliminary report, rates of amino acid loss were significantly greater in subjects with RTT than controls, indicating failure to suppress endogenous body protein degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/72\">",
"     72",
"    </a>",
"    ]. In a cohort of 92 girls with RTT, gastrostomy placement for nutritional supplementation was associated with statistically significant increases in Z score slopes for height, weight, and body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884448\">",
"    <span class=\"h3\">",
"     Feeding impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeding impairment, characterized as chewing or swallowing difficulties, choking, and nasal regurgitation, frequently complicates RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/74-80\">",
"     74-80",
"    </a>",
"    ]. In addition to oromotor dysfunction, the upper gastrointestinal (UGI) tract may be affected. In a study of 34 females with RTT ages 2 to 40 years, oropharyngeal dysfunction and UGI dysmotility occurred in 95 and 68 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/81\">",
"     81",
"    </a>",
"    ]. Abnormalities of oropharyngeal function included poor tongue mobility, reduced oropharyngeal clearance, and laryngeal penetration of liquids and solid foods during swallowing. Esophageal dysmotility, characterized by the absence of primary or secondary waves, delayed emptying, atony, the presence of tertiary waves, or spasm was found in 11 patients (39 percent). Gastroesophageal reflux was present in 11 patients (35 percent), including one with nasopharyngeal reflux. Six patients (20 percent) had gastric dysmotility, characterized as decreased peristalsis or atony, and one had duodenal dysmotility.",
"   </p>",
"   <p>",
"    In another study, decreased dietary energy intake was associated with poor chewing and persistence of liquid and solid food residue in the pyriform sinuses and valleculae, as well as decreased body fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33395658\">",
"    <span class=\"h2\">",
"     Epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur in the majority of patients with RTT. The largest study, from the Rare Disease Network for Rett syndrome, reported 528 patients (ages 8 months to 64 years) who met classic criteria for RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/82\">",
"     82",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, parent-reported seizures affected 360 patients (60 percent), and the frequency was similar for patients with classic and atypical RTT. However, by physician assessment of the clinical description of seizures, epileptic seizures affected 291 patients (48 percent)",
"     </li>",
"     <li>",
"      The prevalence of epilepsy increased with age. Seizures were not reported before age two, but thereafter the proportion affected by seizures was as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      2 to &lt;5 years, approximately 33 percent",
"     </li>",
"     <li>",
"      5 to &lt;10 years, 60 percent",
"     </li>",
"     <li>",
"      10 to &lt;15 years, 77 percent",
"     </li>",
"     <li>",
"      15 to &lt;30 years, 84 percent",
"     </li>",
"     <li>",
"      &ge;30 years old, 86 percent",
"      <br/>",
"      <br/>",
"      Beyond age 30, there was no increase in proportion with epilepsy, suggesting that late onset of seizures in adults with RTT is unlikely",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with RTT who are affected by epilepsy, the seizure frequency varied widely, with no seizures for six months prior to evaluation, monthly seizures, weekly seizures, and daily seizures in 36, 27, 20, and 11 percent, respectively",
"     </li>",
"     <li>",
"      After adjustment for age, the occurrence of seizures was associated with higher scores for clinical severity of RTT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other smaller studies have reported a higher prevalence of seizures in RTT. As an example, a series from Sweden reported that epilepsy affected 50 of 53 patients with RTT (94 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/83\">",
"     83",
"    </a>",
"    ]. Two of the nine deaths that occurred were associated with seizures (aspiration and status epilepticus). Patients in the series had all seizure types except for typical absences and clonic seizures. The most common were complex partial, tonic-clonic, tonic, and myoclonic seizures. In this series, intractable (medically refractory) epilepsy was observed in approximately one-half of the patients.",
"   </p>",
"   <p>",
"    The occurrence of epilepsy in RTT may be overestimated because affected patients have a variety of abnormal behaviors that may be reported as seizure manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. These include breath holding, hyperventilation, incessant hand wringing, \"vacant\" episodes with sudden-absence-like freezing of activity, inappropriate screaming or laughter, and motor abnormalities (dystonia, tremulousness, and limpness). However, these events do not have associated EEG changes. This point was illustrated by a study of",
"    <span class=\"nowrap\">",
"     video/polygraphic/EEG",
"    </span>",
"    monitoring in 82 females with RTT ages 2 to 30 years, all of whom had epileptiform abnormalities on EEG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/87\">",
"     87",
"    </a>",
"    ]. During monitoring, 51 percent of the parents identified events that they thought represented their child's typical seizure, such as twitching, jerking, head turning, falling forward, and trembling, as well as episodes of staring, laughing, pupil dilatation, breath holding, and hyperventilation. However, only 18 percent of these clinical episodes correlated with an EEG seizure discharge. In addition, some electrographic seizures were unrecognized by parents or occurred during sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884455\">",
"    <span class=\"h2\">",
"     Bone mineral deficit and fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone density frequently appears diminished on conventional radiographs in girls with RTT, although the cause is unknown. This is seen in affected children (age two to five years) and adults, whether or not they are ambulatory. Girls with RTT have abnormally low regional bone mineral density and whole-body bone mineral content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. In one study, bone mineral content was measured by dual-energy X-ray absorptiometry in 106 girls with various diseases, including RTT, cystic fibrosis, juvenile dermatomyositis, liver disease, and human immunodeficiency virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/89\">",
"     89",
"    </a>",
"    ]. Bone mineral deficit was greatest in the patients with RTT, who all had severe abnormalities.",
"   </p>",
"   <p>",
"    Girls with RTT have a nearly fourfold increased risk of bone fracture when compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. The risk appears to be associated with the presence of decreased bone thickness, more severe mutations, and the use of antiepileptic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884469\">",
"    <span class=\"h2\">",
"     Cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of sudden, unexpected death is higher in RTT than in the general population (0.3 percent, versus 0.0001 percent for people ages 1 to 22 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. The mechanism is thought to be cardiac electrical instability due to abnormal autonomic nervous system regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/96\">",
"     96",
"    </a>",
"    ]. Increased sympathetic activity is suggested by the increased incidence of prolonged QTc in RTT. In several reports, the incidence of prolonged QTc (&gt;0.45 msec) was higher and heart rate variability was lower in girls with RTT than age-matched healthy girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/84,94,97,98\">",
"     84,94,97,98",
"    </a>",
"    ]. An increased proportion of QTc interval prolongation with advancing RTT clinical stage has been shown by some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/84,94\">",
"     84,94",
"    </a>",
"    ] but not by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal autonomic regulation is also suggested by a study of cardiac vagal tone, cardiac response to baroreflex, and beat-to-beat heart rate measured during rest, hyperventilation, and immediately after hyperventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/99\">",
"     99",
"    </a>",
"    ], and by a report demonstrating an uncoupling of breathing and heart rate control in girls with RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/100\">",
"     100",
"    </a>",
"    ] The authors of the latter study suggested that this uncoupling may represent a mechanism that increases vulnerability to sudden death in RTT. A deficiency in substance P in the central nervous system identified in girls with RTT may contribute to impairment of autonomic nervous system dysfunction, resulting in cardiac dysautonomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 to 70 percent of patients with RTT have clinical features that indicate autonomic nervous system dysfunction with increased sympathetic tone. These include the presence of cold, blue feet",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hands, drooling, and breathing irregularities. In addition, a case report of a patient with RTT suggests that sympathetic tone is increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/103\">",
"     103",
"    </a>",
"    ]. The girl had relief of the vasomotor instability in the ipsilateral foot after an inadvertent unilateral sympathectomy during scoliosis surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884490\">",
"    <span class=\"h2\">",
"     Disorders of respiratory control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic pattern of disordered breathing during wakefulness occurs in 60 to 77 percent of patients with RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/104-107\">",
"     104-107",
"    </a>",
"    ]. This pattern consists of episodes of hyperventilation with concomitant hypocapnia alternating with hypoventilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apnea. The periods of hypoventilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    apnea may last as long as 20 to 120 seconds and result in hypoxemia. Breathing usually is normal between these episodes.",
"   </p>",
"   <p>",
"    Episodes of hyperventilation tend to occur when the child is excited or agitated, and are frequently associated with other stereotypic movements. Apnea that occurs during wakefulness is typically central, although it may be obstructive. These events may be isolated, or precede or follow hyperventilation. During apneic episodes, the child may stare quietly ahead or smile and appear happy with no evidence of distress, despite severe cyanosis.",
"   </p>",
"   <p>",
"    Apnea may occur in inspiration or expiration. In one study using fiber optic endoscopy, significant oxygen desaturation occurred in expiration but not inspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breathing abnormalities may cause severe hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/106\">",
"     106",
"    </a>",
"    ]. In studies recording electroencephalogram (EEG) and breathing in our laboratory, hypoxemia led to electrographic seizures only when it was associated with apnea. Seizures did not occur with disorganized breathing alone, even when oxygen saturation was as low as 30 to 50 percent. The breathing abnormalities during the awake state are not associated with bradycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/107\">",
"     107",
"    </a>",
"    ]. However, these events are frequently misdiagnosed as seizures. The EEG correlate may be characterized by diffuse, high amplitude slowing, a hyperventilatory response that can be mistaken for ictal electrographic changes. The EEG changes depend on severity of the episodes.",
"   </p>",
"   <p>",
"    The breathing pattern during wakefulness does not appear to be related to the RTT stage. The most severe desaturations typically appear in Stage III; these may decrease in frequency and severity during Stage IV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/107\">",
"     107",
"    </a>",
"    ]. The underlying pathophysiology and relationship to the MECP2 mutation are unknown. It has been suggested that the disordered breathing may be due to an abnormality of cortical influences on ventilation or awake control of breathing, rather than brainstem control of ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/85,106\">",
"     85,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The breathing pattern is typically normal during sleep. However, some reports note breathing disturbances during sleep, including apnea, shallow breathing, hypoventilation, and increased periodic breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/105,107,109\">",
"     105,107,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, one small study using high resolution CT imaging found pulmonary lesions suggestive of interstitial lung disease in approximately one-half of patients with RTT and respiratory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/110\">",
"     110",
"    </a>",
"    ]. The pathogenesis and clinical significance of these pulmonary abnormalities is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27884497\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbances affect 80 percent or more of patients with RTT, and are a problem for both the patient and caregivers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/111\">",
"     111",
"    </a>",
"    ]. The symptoms most commonly reported by caregivers are irregular sleep times, including prolonged periods of wakefulness or sleep, periodic nighttime awakenings with disruptive behavior (such as crying, screaming, laughing), and abbreviated total nighttime sleep with increased amounts of daytime sleep.",
"   </p>",
"   <p>",
"    Sleep architecture is abnormal in RTT. In one report, the amount of REM sleep was less than age-matched healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RTT is based upon clinical characteristics. Mutations in MECP2 are neither necessary nor sufficient to make the diagnosis of RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]. For the diagnosis of typical (classic) RTT, affected children should meet all necessary criteria and have none of the criteria for exclusion. The current criteria recommend consideration of the diagnosis when postnatal deceleration of head growth is observed. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Detection of mutations in the MECP2 gene may be helpful for the diagnosis of RTT. However, this abnormality is not present in all cases; MECP2 mutations are found in approximately 95 percent of those with typical RTT and 20 percent of atypical cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, MECP2 mutations have been identified in individuals who lack the clinical features of RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of RTT in middle childhood is usually straightforward because of the distinctive presentation, although a history that confirms a period of regression must be present. However, the diagnosis in early infancy may be more difficult. The diagnosis cannot be made definitively in the young child with decreasing head growth and delayed gross motor skills until she reaches the regression phase with loss of hand skills and spoken language, onset of hand stereotypies, and gait abnormalities. The diagnosis can usually be made in an adult mentally retarded woman with typical signs, including the prominence of motor problems with progression from a hyperkinetic to a bradykinetic state, and lower motor neuron features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2,112,113\">",
"     2,112,113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22967010\">",
"    <span class=\"h2\">",
"     Typical and atypical Rett syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical phenotype of RTT is broad. In the past, three diagnostic categories (classic, provisional, and atypical) were proposed. These were revised in 2010 to two categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Typical (classic) RTT",
"     </li>",
"     <li>",
"      Atypical (variant) RTT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typical Rett syndrome includes individuals who meet all specific diagnostic criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis should be confirmed by genetic testing. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Atypical Rett syndrome includes girls who have had a clear period of regression and have at least two of the four main criteria and 5 of 11 supportive criteria. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Required for atypical or variant RTT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22967440\">",
"    <span class=\"h2\">",
"     Defined variant forms of RTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three defined variant forms of RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2,114\">",
"     2,114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preserved speech variant (Zappella variant)",
"     </li>",
"     <li>",
"      Early seizure variant (Hanefeld variant)",
"     </li>",
"     <li>",
"      Congenital variant (Rolando variant)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preserved speech variant (or Zappella variant) of RTT is a less severe form of the syndrome that is characterized by recovery of language after regression, with most girls able to speak in sentences, and generally milder expression of typical RTT features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. The majority of girls with this variant have pathogenic MECP2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early-onset seizure variant (or Hanefeld variant) of RTT is caused by mutations in the CDKL5 gene and is characterized by a Rett-like picture with the onset of epilepsy between the first week and fifth month of life as a significant feature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/117-121\">",
"     117-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The congenital variant (or Rolando variant) of RTT caused by mutations in the FOXG1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/122-124\">",
"     122-124",
"    </a>",
"    ] is distinct from RTT due to MECP2 mutation by onset within the first six months of life.",
"   </p>",
"   <p>",
"    Individuals with an MECP2 mutation who do not fulfill the criteria for either typical or atypical RTT are classified as having an MECP2-related disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for RTT, revised in 2010, are divided into main, exclusionary, and supportive categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]. In a preamble, the 2010 RTT diagnostic criteria recommend consideration of the diagnosis when postnatal deceleration of head growth is observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22966698\">",
"    <span class=\"h3\">",
"     Required for typical or classic RTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the diagnosis of typical or classic RTT, the following are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A period of regression followed by recovery or stabilization",
"     </li>",
"     <li>",
"      Meet all main criteria and no exclusionary criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main criteria for RTT are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Partial or complete loss of acquired purposeful hand skills",
"     </li>",
"     <li>",
"      Partial or complete loss of acquired spoken language",
"     </li>",
"     <li>",
"      Gait abnormalities: impaired (dyspraxic) or absence of ability",
"     </li>",
"     <li>",
"      Stereotypic hand movements such as hand",
"      <span class=\"nowrap\">",
"       wringing/squeezing,",
"      </span>",
"      <span class=\"nowrap\">",
"       clapping/tapping,",
"      </span>",
"      mouthing, and",
"      <span class=\"nowrap\">",
"       washing/rubbing",
"      </span>",
"      automatisms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exclusionary criteria for typical RTT are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or severe infection that causes neurologic problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grossly abnormal psychomotor development in first six months of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria described below are not required, although they are frequently present in typical RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Required for atypical or variant RTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the diagnosis of atypical or variant RTT, the following are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A period of regression followed by recovery or stabilization",
"     </li>",
"     <li>",
"      Meet at least two of the four main criteria above",
"     </li>",
"     <li>",
"      Meet at least 5 of the 11 supportive criteria below",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Supportive criteria for",
"    <strong>",
"     atypical",
"    </strong>",
"    RTT are the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breathing disturbances when awake",
"     </li>",
"     <li>",
"      Bruxism when awake",
"     </li>",
"     <li>",
"      Impaired sleep pattern",
"     </li>",
"     <li>",
"      Abnormal muscle tone",
"     </li>",
"     <li>",
"      Peripheral vasomotor disturbances",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Scoliosis/kyphosis",
"      </span>",
"     </li>",
"     <li>",
"      Growth retardation",
"     </li>",
"     <li>",
"      Small cold hands and feet",
"     </li>",
"     <li>",
"      Inappropriate",
"      <span class=\"nowrap\">",
"       laughing/screaming",
"      </span>",
"      spells",
"     </li>",
"     <li>",
"      Diminished response to pain",
"     </li>",
"     <li>",
"      Intense eye communication - &lsquo;&lsquo;eye pointing&rsquo;&rsquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107356884\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the age of presentation, the differential diagnosis of RTT includes the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many causes of intellectual impairment and variant forms of RTT, particularly the preserved speech, early seizure, and congenital variants. (See",
"      <a class=\"local\" href=\"#H22967440\">",
"       'Defined variant forms of RTT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autism,",
"      <span class=\"nowrap\">",
"       hearing/visual",
"      </span>",
"      disturbance, encephalitis, and metabolic or degenerative disorders such as neuronal ceroid lipofuscinosis, phenylketonuria, and urea cycle disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35753?source=see_link\">",
"       \"Overview of phenylketonuria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20248?source=see_link\">",
"       \"Urea cycle disorders: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"      </a>",
"      .) Also consider Pitt-Hopkins syndrome caused by mutations in the gene TCF4.",
"     </li>",
"     <li>",
"      Spastic ataxia, cerebral palsy, spinocerebellar degeneration, leukodystrophies, neuroaxonal dystrophy, Lennox-Gastaut syndrome, and Angelman syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=see_link\">",
"       \"Diagnosis and classification of cerebral palsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37433?source=see_link\">",
"       \"Overview of the hereditary ataxias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link\">",
"       \"The spinocerebellar ataxias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1352?source=see_link&amp;anchor=H17#H17\">",
"       \"Differential diagnosis of acute central nervous system demyelination in children\", section on 'Leukodystrophies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H86261867#H86261867\">",
"       \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unknown degenerative disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22967447\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical evaluation for suspected RTT includes the history and examination and genetic testing. In some cases, additional studies, including an electroencephalogram, may be helpful in the evaluation of RTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history should be obtained from the parents. Special attention should be paid to the timing of developmental milestones and the presence of a period of regression with loss of hand skills and spoken language.",
"   </p>",
"   <p>",
"    Physical examination should identify the characteristic findings of RTT. Measurements typically show impaired growth. Serial measurements often show decelerating head growth, and ultimately, microcephaly. A variety of neurologic manifestations may be seen, including intellectual disability (mental retardation) or developmental delay, loss of or poor communication skills, and stereotypic hand movements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     DNA analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A blood sample should be obtained for DNA analysis to identify mutations of MECP2 in a female with characteristic signs of RTT. Testing should also be considered in male infants with severe encephalopathy. The diagnosis of RTT (MECP2 positive) is made if a pathogenic MECP2 mutation is found and clinical criteria are met.",
"   </p>",
"   <p>",
"    Girls who meet criteria for atypical RTT should be assessed for the presence of clinical features consistent with defined variant forms. For those who have a negative MECP2 analysis, further genetic testing should include analysis for mutations in FOXG1 (if features of the congenital variant are present) or CDKL5 (if features of the early seizure variant are present) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Girls presenting with developmental problems of unknown etiology warrant genetic investigation and consideration of MECP2 testing if they have some features suggestive of RTT. This situation is most likely to arise for individuals younger than three years old.",
"   </p>",
"   <p>",
"    DNA analysis should be offered to the mother if future pregnancies are planned. Prenatal testing is available. Male siblings with neurologic or developmental disorders should also be tested. Female siblings may choose to have testing done when they reach majority age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases where no relevant pathogenic mutation is identified (eg, MECP2, CDKL5, FOXG1), inborn errors of metabolism and neurodegenerative disorders should be considered as part of the general evaluation of a child with developmental delay. Suggested studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain MRI",
"     </li>",
"     <li>",
"      Serum amino acids",
"     </li>",
"     <li>",
"      Urine organic acids",
"     </li>",
"     <li>",
"      Chromosome microarray analysis, with additional genetic testing for Angelman syndrome and SNRPN gene methylation analysis and fluorescent in-situ hybridization or array-based comparative genomic hybridization if clinically indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/125\">",
"       125",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=see_link&amp;anchor=H86261867#H86261867\">",
"       \"Microdeletion syndromes (chromosomes 12 to 22)\", section on '15q11-13 maternal deletion syndrome (Angelman syndrome)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link&amp;anchor=H15538597#H15538597\">",
"       \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Detecting cytogenetic abnormalities'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      White cell enzymes (if regression)",
"     </li>",
"     <li>",
"      Hearing test",
"     </li>",
"     <li>",
"      Ophthalmologic evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient is considered to have RTT without the MECP2 mutation if these studies are nondiagnostic and clinical criteria for RTT are met.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electroencephalogram (EEG) may be helpful in the evaluation of RTT, although it is not used for diagnosis. The EEG is always abnormal in RTT and shows characteristic changes. The epileptiform abnormalities typically begin at approximately two years of age. The EEG subsequently deteriorates with loss of expected developmental features and the appearance of abnormal patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/104\">",
"     104",
"    </a>",
"    ]. These include focal, multifocal, and generalized epileptiform abnormalities, and the occurrence of rhythmic slow (theta) activity primarily in the frontal-central regions.",
"   </p>",
"   <p>",
"    Evoked potentials typically demonstrate intact peripheral auditory and visual pathways and suggest dysfunction of central or higher cortical pathways. Somatosensory evoked potentials may be characterized by \"giant\" responses suggesting cortical hyperexcitability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33394137\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the discovery of MECP2 and subsequent criteria revisions, a staging system was helpful to track the clinical course of RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/126\">",
"     126",
"    </a>",
"    ]. Today it has limited diagnostic utility, but it may be employed as a tool to anticipate potential clinical problems and provide anticipatory guidance to parents. However, it is often difficult to discern precisely the transitions between stages. In addition, this system should",
"    <strong>",
"     not",
"    </strong>",
"    be used to predict life expectancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I consists of developmental arrest. The onset is between 6 to 18 months and it may last for many months. During this time there is less eye contact, reduced play, gross motor delays, nonspecific hand wringing, and decelerating head growth (",
"      <a class=\"graphic graphic_picture graphicRef53558 \" href=\"mobipreview.htm?39/33/40479\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef65333 \" href=\"mobipreview.htm?37/49/38673\">",
"       picture 3",
"      </a>",
"      ). Infants seem placid and not cuddly compared to healthy infants (",
"      <a class=\"graphic graphic_picture graphicRef76864 \" href=\"mobipreview.htm?43/27/44479\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef56128 \" href=\"mobipreview.htm?25/6/25697\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Stage II consists of rapid deterioration or regression. The onset is typically between one to four years. It may be so acute that parents can give a specific date after which their child was no longer normal. In other cases, the onset may be insidious. The duration is usually weeks to months.",
"      <br/>",
"      <br/>",
"      This phase is characterized by the loss of purposeful hand use and spoken language, and the onset during wakefulness of hand stereotypes and periodic breathing irregularities. Hand stereotypes are most frequently midline and hand wringing or hand washing in character. They occur incessantly during wakefulness but cease during sleep, and continue into adulthood (",
"      <a class=\"graphic graphic_picture graphicRef67899 \" href=\"mobipreview.htm?41/21/42320\">",
"       picture 5",
"      </a>",
"      ). During this phase, many affected girls exhibit autistic behavior. Variable periods of unprovoked inconsolable crying or irritability and a disturbed sleep pattern are also common (",
"      <a class=\"graphic graphic_picture graphicRef50936 \" href=\"mobipreview.htm?14/63/15344\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Stage III begins at 2 to 10 years of age, following the period of rapid deterioration. This phase lasts many years and is characterized by behavioral improvement and some improvement in hand use and communication skills, particularly by using &ldquo;eye pointing&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef64268 \" href=\"mobipreview.htm?19/12/19649\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef71900 \" href=\"mobipreview.htm?19/14/19681\">",
"       picture 8",
"      </a>",
"      ). Motor dysfunction (",
"      <a class=\"graphic graphic_picture graphicRef52460 \" href=\"mobipreview.htm?6/45/6866\">",
"       picture 9",
"      </a>",
"      ) and seizures are more prominent during this time.",
"     </li>",
"     <li>",
"      Stage IV consists of late motor deterioration and usually begins after the age of 10 years. It is characterized by increased rigidity, reduced mobility, dystonia, hypomimia, and bradykinesia (",
"      <a class=\"graphic graphic_picture graphicRef78550 \" href=\"mobipreview.htm?24/32/25091\">",
"       picture 10",
"      </a>",
"      ). Some girls and women become non-ambulatory (",
"      <a class=\"graphic graphic_picture graphicRef62752 \" href=\"mobipreview.htm?21/13/21712\">",
"       picture 11",
"      </a>",
"      ) while others continue to ambulate well into adulthood (",
"      <a class=\"graphic graphic_picture graphicRef78909 \" href=\"mobipreview.htm?32/52/33607\">",
"       picture 12",
"      </a>",
"      ). Cognitive function is stable and interpersonal communication may continue to improve. However, spoken communication is not regained. Seizures also often improve. Quadriparesis, scoliosis, and staring may be features of this stage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific therapy is available for RTT. However, a study in mice with a mutation in the Mecp2 gene suggests that early, intensive therapy could be beneficial in RTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/127\">",
"     127",
"    </a>",
"    ]. A blinded placebo-controlled randomized trial found that folate and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23459?source=see_link\">",
"     betaine",
"    </a>",
"    failed to ameliorate any of the clinical features of RTT at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management consists of treating the associated conditions. A multidisciplinary approach is optimal.",
"   </p>",
"   <p>",
"    The first important step in management is confirming the diagnosis of RTT. This is often a relief to families who have searched for an explanation of their child's problems. It may also be the beginning of the grief process for the loss of a normal child. At the time of diagnosis, anticipatory guidance should be provided regarding the spectrum of clinical problems. All parents should be taught cardiopulmonary resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic growth should be closely monitored. A high calorie, well-balanced diet should be provided with vitamins and minerals at the recommended dietary allowance. Energy intake should be increased with high-calorie supplements, either orally or by gastrostomy feeding, if needed to maintain adequate growth. Oromotor function should be assessed by videofluoroscopy in children who have choking, decreased control of secretions, frequent upper or lower respiratory infections, or weight loss. An individualized treatment plan should be developed including appropriate food and beverage consistencies, positioning, and the use of selected feeding utensils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     GI dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of eating difficulty, eructation, emesis, or irritability should be evaluated for possible gastroesophageal reflux disease or delayed gastric emptying. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=see_link\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Constipation can be a severe and chronic problem for many patients. One approach is a program of daily prophylaxis. Options include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/41/26260?source=see_link\">",
"     polyethylene glycol 3350",
"    </a>",
"    1 cap (17 g) dissolved in 8 oz of water, juice, or milk daily with titration up or down to tolerance, or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    once a day with titration down to tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, low bone mineral density is common and may lead to fractures. Affected patients with crying",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    screaming episodes of unknown etiology should be evaluated for fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures may occur during sleep or not be recognized by caregivers. Conversely, many behavioral events identified by parents as seizures are nonepileptic. Thus, video-EEG monitoring may be necessary to differentiate nonepileptic behavioral events from actual seizures and to identify unrecognized seizures.",
"   </p>",
"   <p>",
"    Most seizures are easily controlled and respond to standard antiepileptic drugs. A ketogenic diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/129\">",
"     129",
"    </a>",
"    ] or vagus nerve stimulator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/130,131\">",
"     130,131",
"    </a>",
"    ] may improve intractable seizures. However, in view of the frequent occurrence of growth failure, a ketogenic diet should be used with caution. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormonal therapy or treatment with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    may be helpful in patients with infantile spasms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=see_link\">",
"     \"Management and prognosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Breathing dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known treatment for apnea during wakefulness. In our experience, treatment with supplemental oxygen or rebreathing has not resulted in improvement; rebreathing has occasionally worsened the apnea.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34403?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    have been reported to lessen the severity of disordered breathing. In our experience, these have been beneficial to a small number of girls.",
"   </p>",
"   <p>",
"    Apnea during sleep is not characteristic of RTT. It should be evaluated as in any patient with sleep apnea. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be obtained when the diagnosis of RTT is made. If the QTc interval is &gt;0.45, a cardiologist should be consulted. The ECG should be monitored annually.",
"   </p>",
"   <p>",
"    Medications associated with prolongation of the QT interval (eg, tricyclic antidepressants,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) should be avoided. Beta blockers such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/62/36840?source=see_link\">",
"     propranolol",
"    </a>",
"    may be appropriate in some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Scoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scoliosis should be identified as early as possible. However, the optimal treatment of scoliosis in RTT is uncertain, and high-quality evidence supporting management strategies is limited. Guidelines for the management of scoliosis in patients with RTT, published in 2009, are based largely upon consensus opinion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/132\">",
"     132",
"    </a>",
"    ]. The guidelines recommend a life-span approach that starts prior to the development of scoliosis and involves a comprehensive management team that includes medical, surgical, and therapy specialists. Physical assessment of the spine is recommended at least every six months. Referral to an orthopedic surgeon is recommended when there is clinical concern for scoliosis.",
"   </p>",
"   <p>",
"    Although there is no evidence that physiotherapy can prevent progression of scoliosis, the guidelines recommend a therapy program that aims to prolong ambulation and maintain range of motion and proper seating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/132\">",
"     132",
"    </a>",
"    ]. Bracing to control progression of the scoliosis does not appear to be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/132-134\">",
"     132-134",
"    </a>",
"    ], but it may be used for truncal stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective evidence suggests that surgical management can be beneficial for certain cases of scoliosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/66,135,136\">",
"     66,135,136",
"    </a>",
"    ]; the guidelines recommend consideration of spinal fusion when the Cobb angle is 40 to 50 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Cobb angle'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Sleep disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of sleep disturbance should include characterization of night and daytime routines, time of occurrence and related factors, and impact on the family as a whole. Specific disorders that disturb sleep should be considered, such as sleep apnea secondary to tonsillar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adenoidal hypertrophy, gastroesophageal reflux, and seizures.",
"   </p>",
"   <p>",
"    Behavioral intervention should be attempted to treat dysfunctional sleep patterns. Good sleep habits should be encouraged, including the maintenance of regular day and night routines and allowing the child only to sleep in bed. This approach includes establishing a bedtime conducive to rapid sleep onset, removing the child from the bed if she does not fall asleep within one hour, and avoiding daytime sleep except for scheduled naps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/137\">",
"     137",
"    </a>",
"    ]. Other measures that may be helpful are taking a warm bath one to two hours before sleep, avoiding caffeine, exercising no later than three to four hours before bedtime, and following a routine bedtime ritual. Bright light exposure in the early morning promotes early sleep time, while evening exposure promotes later sleep time and should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic agents are not consistently successful at correcting sleep disorders. Many disrupt the normal sleep architecture",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have persistent effects on the following day. Alternative therapies may include short-acting, non-benzodiazepine receptor agonists such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/61/15318?source=see_link\">",
"     zaleplon",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/38/26215?source=see_link\">",
"     zolpidem",
"    </a>",
"    . Other sleep-inducing agents such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/46/744?source=see_link\">",
"     trazodone",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    have also been utilized. Melatonin has improved sleep disturbances in some patients with RTT, but further studies are needed before it can be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/139-141\">",
"     139-141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Motor dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A program of physical, occupational, and communication therapy should be provided for patients with RTT. Physical therapy is thought to promote ambulation and balance, prevent or retard the development of contractures, and control deformities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/142,143\">",
"     142,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of occupational therapy is to promote purposeful use of the hands. Hand stereotypies can often be diminished by providing elbow or hand restraints. It may only be necessary to restrain the non-dominant hand or elbow. In several small series, splinting to inhibit repetitive hand activity was associated with improvements such as increased socialization and interaction with the environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/142-146\">",
"     142-146",
"    </a>",
"    ]. In our clinical experience, many therapists employ this technique with success. However, larger studies evaluating the effectiveness of hand splints are needed.",
"   </p>",
"   <p>",
"    Communication therapy may enhance communication skills. Observation-based assessment approaches may be useful for communication intervention planning.",
"   </p>",
"   <p>",
"    Other types of therapy may also be helpful, although few data are available to support their use. Music therapy may facilitate sustained focus, attention, and improve interaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/147-149\">",
"     147-149",
"    </a>",
"    ]. Hydrotherapy may promote movement and balance. Horseback riding may promote balance and protective responses that help maintain mobility and avert falls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Reproductive issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Girls with RTT go through puberty, menstruate, and may become pregnant. Issues and options concerning birth control and hygiene should be discussed with parents or guardians of women with RTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400345\">",
"    <span class=\"h2\">",
"     Life expectancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiac abnormalities may predispose patients with RTT to sudden death, survival well into adulthood is typical. This conclusion is supported by an analysis of the North American RTT database comprising patients with typical RTT (n = 1648) and atypical RTT (n = 259) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/29/32218/abstract/150\">",
"     150",
"    </a>",
"    ]. Based upon Kaplan-Meier curves, the median survival of patients with typical RTT was approximately age 45 years. Survival for individuals with atypical RTT was significantly longer than for those with typical RTT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33400376\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rett syndrome (RTT) is caused by mutations in the MECP2 gene, which maps to Xq28 and encodes methyl-CpG binding protein 2 (MeCP2). Commonly, three types of MECP2 mutations occur in RTT: missense, frameshift, and nonsense. The",
"      <span class=\"nowrap\">",
"       genotype/phenotype",
"      </span>",
"      correlation has not been well established. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical picture of typical (classic) RTT is unique. Affected patients initially develop normally, and then lose speech and purposeful hand use and have onset of stereotyped hand movements and gait abnormalities. Deceleration of head growth can be one of the first signs. Seizures, autistic features, ataxia, and intermittent breathing abnormalities develop subsequently. Other serious conditions associated with RTT include cardiac abnormalities that may lead to sudden death, motor dysfunction, scoliosis, and sleep disturbance. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of RTT is based upon clinical characteristics. Affected children should meet all main criteria and have none of the criteria for exclusion. Detection of a mutation in the MECP2 gene may be helpful, but such mutations are not present in all cases of RTT. The diagnosis of RTT in middle childhood is usually straightforward because of the distinctive presentation. However, the diagnosis in early infancy may be more difficult. The diagnosis cannot be made definitively in the young child with decreasing head growth and delayed gross motor skills until she reaches the regression phase and shows other characteristic features of RTT. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending upon the age of presentation, the differential diagnosis of RTT includes the following conditions (see",
"      <a class=\"local\" href=\"#H107356884\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Many causes of intellectual impairment and variant forms of RTT, particularly the preserved speech, early seizure, and congenital variants",
"     </li>",
"     <li>",
"      Autism,",
"      <span class=\"nowrap\">",
"       hearing/visual",
"      </span>",
"      disturbance, encephalitis, and metabolic or degenerative disorders",
"     </li>",
"     <li>",
"      Spastic ataxia, cerebral palsy, spinocerebellar degeneration, leukodystrophies, neuroaxonal dystrophy, Lennox-Gastaut syndrome, and Angelman syndrome",
"     </li>",
"     <li>",
"      An unknown degenerative disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical evaluation for suspected RTT includes the history and examination and genetic testing. In some cases, additional studies including an electroencephalogram may be helpful in the evaluation of RTT. (See",
"      <a class=\"local\" href=\"#H22967447\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of a staging system has limited diagnostic utility, but it can be employed as a tool to anticipate potential clinical problems and provide anticipatory guidance to parents. However, it is often difficult to discern precisely the transitions between stages. (See",
"      <a class=\"local\" href=\"#H33394137\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific therapy is available for RTT. Management consists of treating the associated conditions. A multidisciplinary approach is optimal. A program of physical, occupational, and communication therapy should be provided. Specific issues that commonly require attention in patients with RTT include growth failure and nutrition, epilepsy, breathing dysfunction, cardiac abnormalities, scoliosis, sleep disturbance, and motor dysfunction. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/1\">",
"      Rett A. [On a unusual brain atrophy syndrome in hyperammonemia in childhood]. Wien Med Wochenschr 1966; 116:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/2\">",
"      Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010; 68:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/3\">",
"      Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/4\">",
"      Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992; 51:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/5\">",
"      Cheadle JP, Gill H, Fleming N, et al. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum Mol Genet 2000; 9:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/6\">",
"      Huppke P, Laccone F, Kr&auml;mer N, et al. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet 2000; 9:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/7\">",
"      Bienvenu T, Carri&eacute; A, de Roux N, et al. MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet 2000; 9:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/8\">",
"      Amir RE, Van den Veyver IB, Schultz R, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol 2000; 47:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/9\">",
"      Amano K, Nomura Y, Segawa M, Yamakawa K. Mutational analysis of the MECP2 gene in Japanese patients with Rett syndrome. J Hum Genet 2000; 45:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/10\">",
"      Auranen M, Vanhala R, Vosman M, et al. MECP2 gene analysis in classical Rett syndrome and in patients with Rett-like features. Neurology 2001; 56:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/11\">",
"      Obata K, Matsuishi T, Yamashita Y, et al. Mutation analysis of the methyl-CpG binding protein 2 gene (MECP2) in patients with Rett syndrome. J Med Genet 2000; 37:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/12\">",
"      Xiang F, Buervenich S, Nicolao P, et al. Mutation screening in Rett syndrome patients. J Med Genet 2000; 37:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/13\">",
"      Percy AK, Lane JB, Childers J, et al. Rett syndrome: North American database. J Child Neurol 2007; 22:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/14\">",
"      Hoffbuhr K, Devaney JM, LaFleur B, et al. MeCP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001; 56:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/15\">",
"      Inui K, Akagi M, Ono J, et al. Mutational analysis of MECP2 in Japanese patients with atypical Rett syndrome. Brain Dev 2001; 23:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/16\">",
"      Percy AK, Neul JL, Glaze DG, et al. Rett syndrome diagnostic criteria: lessons from the Natural History Study. Ann Neurol 2010; 68:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/17\">",
"      Trappe R, Laccone F, Cobilanschi J, et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 2001; 68:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/18\">",
"      Wan M, Lee SS, Zhang X, et al. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 1999; 65:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/19\">",
"      Orrico A, Lam C, Galli L, et al. MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 2000; 481:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/20\">",
"      Meloni I, Bruttini M, Longo I, et al. A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 2000; 67:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/21\">",
"      Villard L, Kpebe A, Cardoso C, et al. Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 2000; 55:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/22\">",
"      Clayton-Smith J, Watson P, Ramsden S, Black GC. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 2000; 356:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/23\">",
"      Moog U, Van Roozendaal K, Smeets E, et al. MECP2 mutations are an infrequent cause of mental retardation associated with neurological problems in male patients. Brain Dev 2006; 28:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/24\">",
"      Ohki I, Shimotake N, Fujita N, et al. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 2001; 105:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/25\">",
"      Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/26\">",
"      Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/27\">",
"      Tudor M, Akbarian S, Chen RZ, Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci U S A 2002; 99:15536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/28\">",
"      Traynor J, Agarwal P, Lazzeroni L, Francke U. Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med Genet 2002; 3:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/29\">",
"      Pescucci C, Meloni I, Renieri A. Is Rett syndrome a loss-of-imprinting disorder? Nat Genet 2005; 37:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/30\">",
"      Balmer D, Arredondo J, Samaco RC, LaSalle JM. MECP2 mutations in Rett syndrome adversely affect lymphocyte growth, but do not affect imprinted gene expression in blood or brain. Hum Genet 2002; 110:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/31\">",
"      Horike S, Cai S, Miyano M, et al. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 2005; 37:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/32\">",
"      Sch&uuml;le B, Li HH, Fisch-Kohl C, et al. DLX5 and DLX6 expression is biallelic and not modulated by MeCP2 deficiency. Am J Hum Genet 2007; 81:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/33\">",
"      Christodoulou J, Grimm A, Maher T, Bennetts B. RettBASE: The IRSA MECP2 variation database-a new mutation database in evolution. Hum Mutat 2003; 21:466.",
"     </a>",
"    </li>",
"    <li>",
"     Christodoulou, J, Ho, G. MECP2-related disorders. GeneReviews. file://www.ncbi.nlm.nih.gov/books/NBK1497/ (Accessed on December 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/35\">",
"      Colvin L, Leonard H, de Klerk N, et al. Refining the phenotype of common mutations in Rett syndrome. J Med Genet 2004; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/36\">",
"      Bebbington A, Anderson A, Ravine D, et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 2008; 70:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/37\">",
"      Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 2008; 70:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/38\">",
"      Archer H, Evans J, Leonard H, et al. Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation. J Med Genet 2007; 44:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/39\">",
"      Zhang Y, Minassian BA. Will my Rett syndrome patient walk, talk, and use her hands? Neurology 2008; 70:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/40\">",
"      Armstrong DD, Dunn JK, Schultz RJ, et al. Organ growth in Rett syndrome: a postmortem examination analysis. Pediatr Neurol 1999; 20:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/41\">",
"      Jellinger K, Armstrong D, Zoghbi HY, Percy AK. Neuropathology of Rett syndrome. Acta Neuropathol 1988; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/42\">",
"      Casanova MF, Naidu S, Goldberg TE, et al. Quantitative magnetic resonance imaging in Rett syndrome. J Neuropsychiatry Clin Neurosci 1991; 3:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/43\">",
"      Reiss AL, Faruque F, Naidu S, et al. Neuroanatomy of Rett syndrome: a volumetric imaging study. Ann Neurol 1993; 34:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/44\">",
"      Armstrong DD. Review of Rett syndrome. J Neuropathol Exp Neurol 1997; 56:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/45\">",
"      Bauman ML, Kemper TL, Arin DM. Pervasive neuroanatomic abnormalities of the brain in three cases of Rett's syndrome. Neurology 1995; 45:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/46\">",
"      Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol 2005; 20:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/47\">",
"      Armstrong D, Dunn JK, Antalffy B, Trivedi R. Selective dendritic alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol 1995; 54:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/48\">",
"      Kaufmann WE, Naidu S, Budden S. Abnormal expression of microtubule-associated protein 2 (MAP-2) in neocortex in Rett syndrome. Neuropediatrics 1995; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/49\">",
"      Kaufmann WE, Taylor CV, Hohmann CF, et al. Abnormalities in neuronal maturation in Rett syndrome neocortex: preliminary molecular correlates. Eur Child Adolesc Psychiatry 1997; 6 Suppl 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/50\">",
"      Kozinetz CA, Skender ML, MacNaughton N, et al. Epidemiology of Rett syndrome: a population-based registry. Pediatrics 1993; 91:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/51\">",
"      Bienvenu T, Philippe C, De Roux N, et al. The incidence of Rett syndrome in France. Pediatr Neurol 2006; 34:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/52\">",
"      Hagberg B. Rett's syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand 1985; 74:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/53\">",
"      Kerr AM, Stephenson JB. Rett's syndrome in the west of Scotland. Br Med J (Clin Res Ed) 1985; 291:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/54\">",
"      Leonard H, Bower C, English D. The prevalence and incidence of Rett syndrome in Australia. Eur Child Adolesc Psychiatry 1997; 6 Suppl 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/55\">",
"      Hagberg B, Witt-Engerstr&ouml;m I. Rett syndrome: epidemiology and nosology--progress in knowledge 1986--a conference communication. Brain Dev 1987; 9:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/56\">",
"      Einspieler C, Kerr AM, Prechtl HF. Is the early development of girls with Rett disorder really normal? Pediatr Res 2005; 57:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/57\">",
"      Fehr S, Bebbington A, Ellaway C, et al. Altered attainment of developmental milestones influences the age of diagnosis of rett syndrome. J Child Neurol 2011; 26:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/58\">",
"      Hagberg G, Stenbom Y, Witt Engerstr&ouml;m I. Head growth in Rett syndrome. Acta Paediatr 2000; 89:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/59\">",
"      Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 1983; 14:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/60\">",
"      Sigafoos J, Kagohara D, van der Meer L, et al. Communication assessment for individuals with Rett syndrome: A systematic review. Res Autism Spectr Disord 2011; 5:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/61\">",
"      Temudo T, Oliveira P, Santos M, et al. Stereotypies in Rett syndrome: analysis of 83 patients with and without detected MECP2 mutations. Neurology 2007; 68:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/62\">",
"      FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord 1990; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/63\">",
"      Colvin L, Fyfe S, Leonard S, et al. Describing the phenotype in Rett syndrome using a population database. Arch Dis Child 2003; 88:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/64\">",
"      Ager S, Fyfe S, Christodoulou J, et al. Predictors of scoliosis in Rett syndrome. J Child Neurol 2006; 21:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/65\">",
"      Percy AK, Lee HS, Neul JL, et al. Profiling scoliosis in Rett syndrome. Pediatr Res 2010; 67:435.",
"     </a>",
"    </li>",
"    <li>",
"     Stokland, E, Lidstr&ouml;m, J, Hagberg, B. Scoliosis in Rett syndrome. In: Clinical and Biological Aspects, Hagberg, B (Ed), MacKeith Press, London 1993. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/67\">",
"      Tarquinio DC, Motil KJ, Hou W, et al. Growth failure and outcome in Rett syndrome: specific growth references. Neurology 2012; 79:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/68\">",
"      Schultz R, Glaze D, Motil K, et al. Hand and foot growth failure in Rett syndrome. J Child Neurol 1998; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/69\">",
"      Motil KJ, Schultz RJ, Wong WW, Glaze DG. Increased energy expenditure associated with repetitive involuntary movement does not contribute to growth failure in girls with Rett syndrome. J Pediatr 1998; 132:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/70\">",
"      Motil KJ, Schultz R, Brown B, et al. Altered energy balance may account for growth failure in Rett syndrome. J Child Neurol 1994; 9:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/71\">",
"      Motil, KJ, Schultz, RJ, Glaze, DG. Dietary energy supplementation reverses cranial, linear, and ponderal growth failure in girls with Rett syndrome. Pediatr Res 1996; 39:378A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/72\">",
"      Motil, KJ, Schultz, RJ, Kertz, B, et al. Increased body protein degradation is associated with lean body mass deficits in girls with Rett syndrome. FASEB J 1999; 13:A9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/73\">",
"      Motil KJ, Morrissey M, Caeg E, et al. Gastrostomy placement improves height and weight gain in girls with Rett syndrome. J Pediatr Gastroenterol Nutr 2009; 49:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/74\">",
"      Morton RE, Bonas R, Minford J, et al. Feeding ability in Rett syndrome. Dev Med Child Neurol 1997; 39:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/75\">",
"      Budden SS. Management of Rett syndrome: a ten year experience. Neuropediatrics 1995; 26:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/76\">",
"      Rice MA, Haas RH. The nutritional aspects of Rett syndrome. J Child Neurol 1988; 3 Suppl:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/77\">",
"      Thommessen M, Heiberg A, Kase BF, et al. Feeding problems, height and weight in different groups of disabled children. Acta Paediatr Scand 1991; 80:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/78\">",
"      Thommessen M, Kase BF, Heiberg A. Growth and nutrition in 10 girls with Rett syndrome. Acta Paediatr 1992; 81:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/79\">",
"      Motil KJ, Schultz RJ, Browning K, et al. Oropharyngeal dysfunction and gastroesophageal dysmotility are present in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr 1999; 29:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/80\">",
"      Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J Pediatr Gastroenterol Nutr 2012; 55:292.",
"     </a>",
"    </li>",
"    <li>",
"     Motil, KJ, Schultz, RJ, Glaze, DG, Armstrong, D. Oropharyngeal dysfunction and upper gastrointestinal dysmotility, a reflection of disturbances in the autonomic nervous system in Rett syndrome. In: Rett Disorder and the Developing Brain, Kerr, A, Witt-Engerstr&ouml;m, I (Eds), Oxford University Press, Oxford 2001. p.259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/82\">",
"      Glaze DG, Percy AK, Skinner S, et al. Epilepsy and the natural history of Rett syndrome. Neurology 2010; 74:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/83\">",
"      Steffenburg U, Hagberg G, Hagberg B. Epilepsy in a representative series of Rett syndrome. Acta Paediatr 2001; 90:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/84\">",
"      Guideri F, Acampa M, Hayek G, et al. Reduced heart rate variability in patients affected with Rett syndrome. A possible explanation for sudden death. Neuropediatrics 1999; 30:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/85\">",
"      Glaze DG, Frost JD Jr, Zoghbi HY, Percy AK. Rett's syndrome: characterization of respiratory patterns and sleep. Ann Neurol 1987; 21:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/86\">",
"      Kerr AM. Early clinical signs in the Rett disorder. Neuropediatrics 1995; 26:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/87\">",
"      Glaze DG, Schultz RJ, Frost JD. Rett syndrome: characterization of seizures versus non-seizures. Electroencephalogr Clin Neurophysiol 1998; 106:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/88\">",
"      Haas RH, Dixon SD, Sartoris DJ, Hennessy MJ. Osteopenia in Rett syndrome. J Pediatr 1997; 131:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/89\">",
"      Ellis KJ, Shypailo RJ, Hardin DS, et al. Z score prediction model for assessment of bone mineral content in pediatric diseases. J Bone Miner Res 2001; 16:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/90\">",
"      Motil KJ, Ellis KJ, Barrish JO, et al. Bone mineral content and bone mineral density are lower in older than in younger females with Rett syndrome. Pediatr Res 2008; 64:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/91\">",
"      Leonard H, Thomson MR, Glasson EJ, et al. A population-based approach to the investigation of osteopenia in Rett syndrome. Dev Med Child Neurol 1999; 41:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/92\">",
"      Downs J, Bebbington A, Woodhead H, et al. Early determinants of fractures in Rett syndrome. Pediatrics 2008; 121:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/93\">",
"      Kerr AM, Armstrong DD, Prescott RJ, et al. Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry 1997; 6 Suppl 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/94\">",
"      Sekul EA, Moak JP, Schultz RJ, et al. Electrocardiographic findings in Rett syndrome: an explanation for sudden death? J Pediatr 1994; 125:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/95\">",
"      Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol 1985; 5:118B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/96\">",
"      Acampa M, Guideri F. Cardiac disease and Rett syndrome. Arch Dis Child 2006; 91:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/97\">",
"      Ellaway CJ, Sholler G, Leonard H, Christodoulou J. Prolonged QT interval in Rett syndrome. Arch Dis Child 1999; 80:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/98\">",
"      Fuster-Siebert M, Castro-Gago M. Electrocardiographic findings in Rett syndrome. J Pediatr 1995; 126:506.",
"     </a>",
"    </li>",
"    <li>",
"     Julu, POO. The Central Autonomic Disturbance in Rett Syndrome. In: Rett Disorder and the Developing Brain, Kerr, A, and Witt-Engerstr&ouml;m, I (Eds). Oxford University Press, Oxford 2001. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/100\">",
"      Weese-Mayer DE, Lieske SP, Boothby CM, et al. Autonomic dysregulation in young girls with Rett Syndrome during nighttime in-home recordings. Pediatr Pulmonol 2008; 43:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/101\">",
"      Deguchi K, Antalffy BA, Twohill LJ, et al. Substance P immunoreactivity in Rett syndrome. Pediatr Neurol 2000; 22:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/102\">",
"      Matsuishi T, Nagamitsu S, Yamashita Y, et al. Decreased cerebrospinal fluid levels of substance P in patients with Rett syndrome. Ann Neurol 1997; 42:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/103\">",
"      Naidu S, Chatterjee S, Murphy M, et al. Rett syndrome: new observations. Brain Dev 1987; 9:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/104\">",
"      Glaze DG, Frost JD Jr, Zoghbi HY, Percy AK. Rett's syndrome. Correlation of electroencephalographic characteristics with clinical staging. Arch Neurol 1987; 44:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/105\">",
"      Southall DP, Kerr AM, Tirosh E, et al. Hyperventilation in the awake state: potentially treatable component of Rett syndrome. Arch Dis Child 1988; 63:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/106\">",
"      Cirignotta F, Lugaresi E, Montagna P. Breathing impairment in Rett syndrome. Am J Med Genet Suppl 1986; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/107\">",
"      Marcus CL, Carroll JL, McColley SA, et al. Polysomnographic characteristics of patients with Rett syndrome. J Pediatr 1994; 125:218.",
"     </a>",
"    </li>",
"    <li>",
"     Hiatt, PW, Glaze, DG, Frost, JD Jr. Air flow obstruction in children with Rett Syndrome. Ann Neurol 1989; 26:487 (abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/109\">",
"      Rohdin M, Fernell E, Eriksson M, et al. Disturbances in cardiorespiratory function during day and night in Rett syndrome. Pediatr Neurol 2007; 37:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/110\">",
"      De Felice C, Guazzi G, Rossi M, et al. Unrecognized lung disease in classic Rett syndrome: a physiologic and high-resolution CT imaging study. Chest 2010; 138:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/111\">",
"      Young D, Nagarajan L, de Klerk N, et al. Sleep problems in Rett syndrome. Brain Dev 2007; 29:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/112\">",
"      Hagberg BA, Skjeldal OH. Rett variants: a suggested model for inclusion criteria. Pediatr Neurol 1994; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/113\">",
"      FitzGerald PM, Jankovic J, Glaze DG, et al. Extrapyramidal involvement in Rett's syndrome. Neurology 1990; 40:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/114\">",
"      Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11 September 2001. Eur J Paediatr Neurol 2002; 6:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/115\">",
"      Zappella M. The Rett girls with preserved speech. Brain Dev 1992; 14:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/116\">",
"      Renieri A, Mari F, Mencarelli MA, et al. Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant). Brain Dev 2009; 31:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/117\">",
"      Artuso R, Mencarelli MA, Polli R, et al. Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain Dev 2010; 32:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/118\">",
"      Scala E, Ariani F, Mari F, et al. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J Med Genet 2005; 42:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/119\">",
"      Evans JC, Archer HL, Colley JP, et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet 2005; 13:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/120\">",
"      Bahi-Buisson N, Nectoux J, Rosas-Vargas H, et al. Key clinical features to identify girls with CDKL5 mutations. Brain 2008; 131:2647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/121\">",
"      Russo S, Marchi M, Cogliati F, et al. Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes. Neurogenetics 2009; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/122\">",
"      Ariani F, Hayek G, Rondinella D, et al. FOXG1 is responsible for the congenital variant of Rett syndrome. Am J Hum Genet 2008; 83:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/123\">",
"      Mencarelli MA, Spanhol-Rosseto A, Artuso R, et al. Novel FOXG1 mutations associated with the congenital variant of Rett syndrome. J Med Genet 2010; 47:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/124\">",
"      Philippe C, Amsallem D, Francannet C, et al. Phenotypic variability in Rett syndrome associated with FOXG1 mutations in females. J Med Genet 2010; 47:59.",
"     </a>",
"    </li>",
"    <li>",
"     Williams, CA, Dagli, AI, Driscoll, DJ. Angelman syndrome. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1144/ (Accessed on December 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/126\">",
"      Hagberg B, Witt-Engerstr&ouml;m I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. Am J Med Genet Suppl 1986; 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/127\">",
"      Noutel J, Hong YK, Leu B, et al. Experience-dependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 2011; 70:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/128\">",
"      Glaze DG, Percy AK, Motil KJ, et al. A study of the treatment of Rett syndrome with folate and betaine. J Child Neurol 2009; 24:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/129\">",
"      Haas RH, Rice MA, Trauner DA, Merritt TA. Therapeutic effects of a ketogenic diet in Rett syndrome. Am J Med Genet Suppl 1986; 1:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/130\">",
"      Valencia I, Holder DL, Helmers SL, et al. Vagus nerve stimulation in pediatric epilepsy: a review. Pediatr Neurol 2001; 25:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/131\">",
"      Wilfong AA, Schultz RJ. Vagus nerve stimulation for treatment of epilepsy in Rett syndrome. Dev Med Child Neurol 2006; 48:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/132\">",
"      Downs J, Bergman A, Carter P, et al. Guidelines for management of scoliosis in Rett syndrome patients based on expert consensus and clinical evidence. Spine (Phila Pa 1976) 2009; 34:E607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/133\">",
"      Harrison DJ, Webb PJ. Scoliosis in the Rett syndrome: natural history and treatment. Brain Dev 1990; 12:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/134\">",
"      Bassett GS, Tolo VT. The incidence and natural history of scoliosis in Rett syndrome. Dev Med Child Neurol 1990; 32:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/135\">",
"      Thorey F, J&auml;ger M, Seller K, et al. How to prevent small stature in Rett syndrome-associated collapsing spine syndrome. J Child Neurol 2007; 22:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/136\">",
"      Kerr AM, Webb P, Prescott RJ, Milne Y. Results of surgery for scoliosis in Rett syndrome. J Child Neurol 2003; 18:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/137\">",
"      Piazza CC, Fisher W, Moser H. Behavioral treatment of sleep dysfunction in patients with the Rett syndrome. Brain Dev 1991; 13:232.",
"     </a>",
"    </li>",
"    <li>",
"     Ferber, R, Kryger, M. Principles and Practice of Sleep Medicine in the Child, 1st ed, WB Saunders, Philadelphia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/139\">",
"      McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol 1998; 40:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/140\">",
"      Miyamoto A, Oki J, Takahashi S, Okuno A. Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome. Brain Dev 1999; 21:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/141\">",
"      Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998; 351:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/142\">",
"      Hanks SB. Motor disabilities in the Rett syndrome and physical therapy strategies. Brain Dev 1990; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     International Rett Syndrome Association, Educational and Therapeutic Intervention in Rett Syndrome, 2nd ed, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/144\">",
"      Sharpe PA. Comparative effects of bilateral hand splints and an elbow orthosis on stereotypic hand movements and toy play in two children with Rett syndrome. Am J Occup Ther 1992; 46:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/145\">",
"      Naganuma GM, Billingsley FF. Effect of hand splints on stereotypic hand behavior of three girls with Rett syndrome. Phys Ther 1988; 68:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/146\">",
"      Aron M. The use and effectiveness of elbow splints in the Rett syndrome. Brain Dev 1990; 12:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/147\">",
"      Wigram T, Lawrence M. Music therapy as a tool for assessing hand use and communicativeness in children with Rett Syndrome. Brain Dev 2005; 27 Suppl 1:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/148\">",
"      Yasuhara A, Sugiyama Y. Music therapy for children with Rett syndrome. Brain Dev 2001; 23 Suppl 1:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/149\">",
"      Elefant C, Wigram T. Learning ability in children with Rett syndrome. Brain Dev 2005; 27 Suppl 1:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/29/32218/abstract/150\">",
"      Kirby RS, Lane JB, Childers J, et al. Longevity in Rett syndrome: analysis of the North American Database. J Pediatr 2010; 156:135.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6178 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32218=[""].join("\n");
var outline_f31_29_32218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33400376\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genotype-phenotype correlations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NEUROPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33403553\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107356647\">",
"      Loss of spoken language",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107358573\">",
"      Motor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107358580\">",
"      - Scoliosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27884434\">",
"      Growth failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27884441\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27884448\">",
"      - Feeding impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33395658\">",
"      Epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27884455\">",
"      Bone mineral deficit and fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27884469\">",
"      Cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27884490\">",
"      Disorders of respiratory control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27884497\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22967010\">",
"      Typical and atypical Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22967440\">",
"      Defined variant forms of RTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22966698\">",
"      - Required for typical or classic RTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Required for atypical or variant RTT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107356884\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22967447\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DNA analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33394137\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - GI dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Breathing dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Scoliosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Sleep disturbance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Motor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Reproductive issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33400345\">",
"      Life expectancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33400376\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6178|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/33/40479\" title=\"picture 1\">",
"      RTT prior to developmental arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/27/44479\" title=\"picture 2\">",
"      RTT six months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/49/38673\" title=\"picture 3\">",
"      RTT develop arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/6/25697\" title=\"picture 4\">",
"      RTT onset developmental arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/21/42320\" title=\"picture 5\">",
"      RTT unique hand pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/63/15344\" title=\"picture 6\">",
"      RTT regression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/12/19649\" title=\"picture 7\">",
"      RTT pseudostationary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/14/19681\" title=\"picture 8\">",
"      RTT pseudostationary b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/45/6866\" title=\"picture 9\">",
"      RTT motor dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/32/25091\" title=\"picture 10\">",
"      RTT after 10 years of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/13/21712\" title=\"picture 11\">",
"      RTT late deterioration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/52/33607\" title=\"picture 12\">",
"      RTT 20 years of age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=related_link\">",
"      Diagnosis and classification of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1352?source=related_link\">",
"      Differential diagnosis of acute central nervous system demyelination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/44/11978?source=related_link\">",
"      Microdeletion syndromes (chromosomes 12 to 22)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_29_32219="Glucocorticoid resistant asthma";
var content_f31_29_32219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glucocorticoid resistant asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucocorticoid resistant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucocorticoid responsive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male/female distribution",
"       </td>",
"       <td>",
"        38/20",
"       </td>",
"       <td>",
"        38/20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average age (years)",
"       </td>",
"       <td>",
"        42.8",
"       </td>",
"       <td>",
"        43.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number (percent) with chronic asthma for &lt;5 years",
"       </td>",
"       <td>",
"        35 (60)*",
"       </td>",
"       <td>",
"        19 (33)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number (percent) of current smokers",
"       </td>",
"       <td>",
"        5 (9)",
"       </td>",
"       <td>",
"        12 (21)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number (percent) with family history of asthma",
"       </td>",
"       <td>",
"        36 (62)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        17 (29)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number (percent) atopic on skin testing",
"       </td>",
"       <td>",
"        31 (53)",
"       </td>",
"       <td>",
"        37 (64)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of clinical findings in patients with glucocorticoid resistant and glucocorticoid responsive chronic asthma.",
"    <div class=\"footnotes\">",
"     * p&lt;0.01.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      p&lt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Carmichael J, Paterson IC, Diaz P, et al, Br Med J 1981; 282:1419.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32219=[""].join("\n");
var outline_f31_29_32219=null;
var title_f31_29_32220="Tx acute HAE";
var content_f31_29_32220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F87450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F87450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of acute episodes of hereditary angioedema in adults and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Availability",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         C1 inhibitor concentrate (plasma-derived)",
"        </p>",
"        (Berinert, Berinert P) (Cinryze)",
"       </td>",
"       <td>",
"        In US:",
"        <ul>",
"         <li>",
"          Berinert",
"         </li>",
"         <li>",
"          Cinryze",
"         </li>",
"        </ul>",
"        Other countries:",
"        <ul>",
"         <li>",
"          Berinert P",
"         </li>",
"         <li>",
"          Cinryze",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        20 units per kg body weight given IV over 10 minutes. Symptoms usually stabilize in 30 minutes. Second dose uncommonly needed but may be given 30 minutes to&nbsp;two hours after first.",
"       </td>",
"       <td>",
"        Do not shake solution because protein will denature. Cinryze not FDA-approved for acute attacks, but has efficacy.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Recombinant C1 inhibitor",
"        </p>",
"        Conestat alfa (Ruconest) (Rhucin)",
"       </td>",
"       <td>",
"        Europe only",
"       </td>",
"       <td>",
"        50 units per kg body weight. Second dose rarely needed.",
"       </td>",
"       <td>",
"        Patients should be screened for rabbit allergy prior to receiving, with rabbit-specific IgE immunoassay and not receive drug if positive.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Bradykinin B2 receptor antagonist",
"        </p>",
"        Icatibant (Firazyr)",
"       </td>",
"       <td>",
"        US and many other countries",
"       </td>",
"       <td>",
"        30 mg slow subcutaneous infusion (because of volume) in abdominal area. Second dose needed in about 10 percent of patients and can be given six hours after first. Max of three doses in 25 hours.",
"       </td>",
"       <td>",
"        Caution in patients with unstable angina. Mild injection site reactions are common.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Kallikrein inhibitor",
"        </p>",
"        Ecallantide (Kalbitor)",
"       </td>",
"       <td>",
"        US only",
"       </td>",
"       <td>",
"        30 mg (3 doses of 10 mg each) given at three separate sites, subcutaneously in abdomen, upper arm, or thigh and away from site of angioedema.",
"       </td>",
"       <td>",
"        Rare allergy reaction reported usually in &lt;1 hour. Should be administered by a clinician or nurse in a medical facility equipped to treat anaphylaxis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Solvent detergent treated plasma (S/D plasma) (preferred)",
"         </li>",
"         <li>",
"          Fresh frozen plasma (FFP)&nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        2 units initially. Can be repeated every two to four hours if needed.",
"       </td>",
"       <td>",
"        Monitor for volume overload in patients with underlying conditions predisposing to volume overload. Theoretical risk of transmission of blood borne pathogens.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32220=[""].join("\n");
var outline_f31_29_32220=null;
var title_f31_29_32221="Survival stenting in diabetes";
var content_f31_29_32221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diabetics undergoing stenting have lower event-free survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 283px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to nondiabetic patients receiving a stent, diabetic patients undergoing stent placement have a lower one-year survival free of death, myocardial infarction, and target lesion revascularization (79 versus 73 percent, p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Elezi J, Kastrati A, Pachi S, et al. J Am Coll Cardiol 1998; 32:1866.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32221=[""].join("\n");
var outline_f31_29_32221=null;
var title_f31_29_32222="Recovery rates anaerobes";
var content_f31_29_32222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recovery rates of anaerobic bacteria from differing infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number cultured",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent with anaerobes recovered",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Head and neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nontraumatic brain abscess",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        Heineman et al. Am J Med 1963",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subdural empyema",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        Swartz. Academic Press 1989",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic sinusitis",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        Frederick et al. N Engl J Med 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic otitis",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        Brook. Am J Otolaryngol 1987",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Perimandibular space infection",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        Bartlett et al. J Oral Surg 1979",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Chow et al. Ann Intern Med 1978",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Peritonsillar abscess",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        Flodstrom et al. Scand J Infect Dis 1976",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        Mitchelmore. Eur J Clin Microbiol Infect Dis 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dental abscess",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        Williams et al. J Clin Mirogid 1983",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Chest infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Aspiration pneumonia",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        Bartlett et al. Am Rev Respir Dis 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        Lorber et al. Ann Intern Med 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Lung abscess",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        Bartlett et al. Am Rev Respir Dis 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        Beerens et al. Presses Academiques Euro 1965",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Empyema",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        Bartlett et al. Am Rev Respir Dis 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        Varkey et al. Arch Intern Med, 1981",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchiectasis",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        Greey. 1932",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        Unselected patients",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        Ries et al. Arch Intern Med 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        Pollack et al. J Clin Microbiol 1983",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hospital-acquired pneumonia",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        Bartlett et al. Arch Intern Med, 1986",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Intraabdominal sepsis",
"       </td>",
"       <td>",
"        759",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        Stone et al Arch Surg 1983",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Abscess or peritonitis",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        Gorbach. N Engl J Med, 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        Brook et al. J Med Microbiol 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        Swenson et al. Arch Surg 1974",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Appendiceal abscess",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        Brook et al, Arch Surg 1999",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver abscess",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        Sabbaj et al. Ann Intern Med 1972",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Female genital tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Miscellaneous types",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Thadepalli et al. Am J Obstet Gynecol 1973",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        Swenson et al. Obstet Gynecol 1973",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        Ledger et al. Am J Obstet Gynecol 1976",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic abscess",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        Altemeier. Am J Obstet Gynecol 1940",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"3\">",
"        Pelvic inflammatory disease",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        Eschenbach et al. N Engl J Med 1975",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        Sweet. Clin Infect Dis 1995",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        Sweet et al. Am J Obstet Gynecol 1988",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Septic abortion",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        Chow et al. J Infect Dis 1977",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postpartum endometritis",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        Rosene et al. J Infect Dis 1986",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Soft tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wound infection after elective colon surgery",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        Bartlett et al. Ann Surg 1978",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postappendectomy wound",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        Sanderson et al. J Clin Pathol 1979",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cutaneous abscess",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        Meislin et al. Ann Intern Med 1977",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perirectal abscess",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        Whitehead et al. Br J Surg 1982",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetic foot ulcer",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        Louie et al. Ann Intern Med 1976",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pilonidal sinus",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        Pearson et al. Am J Surg 1968",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breast abscess",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        Edmiston et al. J Infect Dis 1990",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necrotizing synergistic cellulitis",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        Stone et al. Ann Surg 1972",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necrotizing soft tissue",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        Elliott et al. Am J Surg 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paronychia",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        Brook. Am J Surg 1981",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bite wound infections",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        Goldstein et al, Rev Infect Dis 1984",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Bacteremia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"2\">",
"        All blood cultures",
"       </td>",
"       <td>",
"        4659",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Chandler et al. South Med, 2000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2025",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Salonen et al. Clin Infect Dis 1998",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Complete reference citation in text reference list.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32222=[""].join("\n");
var outline_f31_29_32222=null;
var title_f31_29_32223="Stool sample 8 with answer";
var content_f31_29_32223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Entamoeba histolytica cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of stool (x1000) showing a cyst, which could be either Entamoeba histolytica or Entamoeba dispar; these are indistinguishable by morpholgy. However, E. dispar is non-pathogenic and does not cause symptomatic disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_29_32223=[""].join("\n");
var outline_f31_29_32223=null;